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A B S T R A C T
Autophagy and apoptosis are basic physiologic processes contributing to the maintenance of cellular
homeostasis. Autophagy encompasses pathways that target long-lived cytosolic proteins and damaged
organelles. It involves a sequential set of events including double membrane formation, elongation,
vesicle maturation and ﬁnally delivery of the targeted materials to the lysosome. Apoptotic cell death is
best described through its morphology. It is characterized by cell rounding, membrane blebbing,
cytoskeletal collapse, cytoplasmic condensation, and fragmentation, nuclear pyknosis, chromatin
condensation/fragmentation, and formation of membrane-enveloped apoptotic bodies, that are rapidly
phagocytosed by macrophages or neighboring cells. Neurodegenerative disorders are becoming
increasingly prevalent, especially in the Western societies, with larger percentage of members living to
an older age. They have to be seen not only as a health problem, but since they are care-intensive, they
also carry a signiﬁcant economic burden. Deregulation of autophagy plays a pivotal role in the etiology
and/or progress of many of these diseases. Herein, we brieﬂy review the latest ﬁndings that indicate the
involvement of autophagy in neurodegenerative diseases. We provide a brief introduction to autophagy
and apoptosis pathways focusing on the role of mitochondria and lysosomes. We then brieﬂy highlight
pathophysiology of common neurodegenerative disorders like Alzheimer’s diseases, Parkinson’s disease,
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apoptosis in brain homeostasis, especially in the context of the aforementioned disorders. Finally, we
discuss different ways that autophagy and apoptosis modulation may be employed for therapeutic
intervention during the maintenance of neurodegenerative disorders.
 2013 The Authors. Published by Elsevier Ltd.
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In proteopathies, certain proteins become structurally abnor-
mal, accumulate in cells and tissues, and disrupt their function
(Luheshi et al., 2008). Proteopathies include diverse neurodegen-
erative disorders such as Alzheimer’s diseases (AD), Parkinson’s
disease (PD), Huntington’s disease (HD) and Amyotrophic lateral
sclerosis (ALS) in which abnormally assembled proteins appear to
play a central role (Xilouri and Stefanis, 2010). Abnormal or
misfolded proteins, when aggregated in cytoplasmic, nuclear and
extracellular inclusions cause organelle damage and synaptic
dysfunction in the nervous system (Walker and LeVine, 2000). Two
elimination pathways are currently known for damaged cellular
components. Both of them control the quality of cellular
components and maintain cell homeostasis. These are, the
ubiquitin-proteasome system (UPS) that degrades short-lived
proteins in the cytoplasm and nucleus, and the autophagy-
lysosome pathway (ALP) which digests long-lived proteins and
abnormal organelles just in the cytoplasm (Nijholt et al., 2011). The
proper function and balance in the action of these two systems areespecially important in neurons and other long-lived cells. Hence,
their dysfunction contributes to pathogeneses of neurodegenera-
tive diseases (Ciechanover, 2005; Rubinsztein, 2006).
Besides autophagy disturbances, deregulation of apoptosis is
associated with a long list of pathologies, including neurodegen-
erative disorders (Agostini et al., 2011). After multi-cellular
organisms reach adulthood, apoptotic processes remove old and
damaged cells to maintain tissue homeostasis without harming
adjacent cells (Hellwig et al., 2011). With the exception of post-
mitotic cells such as differentiated neurons andmuscle cells, which
are usually highly apoptosis-resistant, themajority of other cells in
the body is regularly renewed, particularly within epithelia,
endothelia and the blood (Hellwig et al., 2011). Hence, recent
reports have emphasized the importance of apoptosis in proteo-
pathies diseases (Agostini et al., 2011; Hellwig et al., 2011).
Below, we brieﬂy introduce autophagy and apoptosis pathways
focusing on the role of mitochondria and lysosomes in both
pathways, followed by autophagy and apoptosis function in brain
homeostasis. Furthermore, some of the most common neurodegen-
erative diseases will be described, then, we explain characteristic
S. Ghavami et al. / Progress in Neurobiology 112 (2014) 24–4926featuresofmacroautophagyandapoptosis. Finally, their signiﬁcance
in the pathogenesis of neurodegenerative diseases as well as
potential therapeutic modulators of these pathways and their
applications in neurodegenerative diseases are highlighted.
2. Cell death
The discovery of cell-embedded mechanism of cell death
pathways in the 20th century lead to the dissolution ofmore than a
century old notions that the natural death is a passive process
(Surova and Zhivotovsky, 2012). Apoptosis and necroptosis are
among major cell death mechanisms and are known as pro-
grammed cell death pathways (PCD) (Lee et al., 2012). Necroptosis
resembles initial apoptotic phenotype, which later on, it propa-
gated by necrotic cell death machinery (Lee et al., 2012). Necrotic
response was ﬁrst reported at least a quarter of a century earlier
than apoptosis, is thought to be due to sudden and drastic stress
(Mughal et al., 2012). Cell swelling, rupture of the cell membrane
and thus triggering inﬂammation in the surrounding cell milieu
characterize necrotic cell death (Galluzzi et al., 2011). However,
recent ﬁndings suggest that at least in some instances necrotic cell
death is regulated, and is triggered by speciﬁc kinase (RIP1 and 3
kinase) pathways, and inhibited by necrostatin1 (Cho et al., 2009;
Holler et al., 2000; Vandenabeele et al., 2010). Moreover, like
apoptosis, necroptosis and autophagy, both are also involved in
homeostasis and embryonic development. Furthermore, at least
some cell death stimuli activate both necrotic and apoptotic
pathway and necrosis becomes visible only if the apoptotic
pathway, that acts faster, is blocked (Los et al., 2002). In addition,
some stimuli may trigger mitochondrial degeneration called
mitoptosis (Jangamreddy and Los, 2012) that in turn may promote
cell death via hyper-autophagy.
3. Autophagy
Autophagy (derived from the Greek words for ‘‘self’’ and
‘‘eating’’), the word by discernment and interpretation comes
across as a self-sacriﬁcingmechanism, which has important role in
cell fate as well as maintaining cell metabolic balance (Eisenberg-
Lerner et al., 2009). For decades, autophagy has been debated as an
active cell death pathway while recently cell survival function of
this pathway has been underlined. Along with previous develop-
mental studies, more recent data support autophagy-induced
caspase-dependent and independent cell death. However, many
unanswered questions remain regarding the interconnecting
regulators of apoptosis and autophagy (Berry and Baehrecke,
2007). Regardless of the controversies, at basal levels autophagy
plays vital role in keeping the cell homeostasis by digestion of
dysfunctional organelles and proteins (Mizushima, 2007). Defec-
tive autophagy pathway or alterations in autophagy-related genes
is shown in various human pathologies including neurodegenera-
tive and lysosomal storage disorders as well as in various cancers
(Mizushima et al., 2008; Ravikumar et al., 2010).
As mentioned in the previous section, autophagy includes three
major types: macroautophagy, microautophagy, and chaperone-
mediated autophagy (CMA). Pathways that lead to organelle-
speciﬁc autophagy (Mitophagy, Ribophagy, Pexophagy, etc.) have
also been recently described (Manjithaya et al., 2010; Suzuki,
2013; Trempe and Fon, 2013). The characterization of these
pathways, however, is at the relatively early stages. Macroauto-
phagy (hereafter called autophagy) is a conserved pathway in
eukaryotic cells that enables the bulk degradation of cytoplasmic
components). The target components are sequestered within
double-membrane vesicle named autophagosome, which are then
transported to the lysosome for degradation, whereas micro-
autophagy is a process that require direct uptake and degradationof cytoplasm by lysosomes, without the involvement of interme-
diate transport vesicles (Glick et al., 2010). CMA can be
distinguished from macro- and microautophagy by its require-
ment for the presence of a consensus pentapeptide sequence,
LysPheGluArgGln, in the substrate protein (SP). The heat shock
proteins (HSP70, a cytosolic chaperone protein) binds to the SP,
and the pentapeptide sequence of the substrate-chaperone
complex are recognized by LAMP2A, the lysosomal CMA receptor.
The SP is the unfolded and translocated across the lysosomal
membrane and is degraded in the lysosome (Cuervo, 2011).
4. Autophagy machinery and its regulation
Autophagy is evolutionarily well conserved from early eukar-
yotes to mammals with as many as 30 Autophagy related genes
(ATGs) identiﬁed in yeasts, and their human orthologs. Autophagic
process involving the ATGs is majorly regulated through mTOR
(mammalian target of rapamycin), which under physiological
conditions inhibits the autophagy by restraining the kinase activity
of ULK (Ubiquitin like Kinase) (Glick et al., 2010). Autophagic
vesicle formation involves initiation, elongation and maturation
steps with subsequent fusion with lysosomes to form autolyso-
some or amphisome (Alavian et al., 2011; Glick et al., 2010). In
mammals, the details of the initial pre-autosomal complex
formation are still not clear. However,the process includes the
de novo formation of initiation complex consisting of ULK complex
with ATG1, ATG13, ATG17 and ATG9, regulatory class III PI3 kinase
complex with beclin-1 (also known as ATG6) and ATG5-ATG12-
ATG16 multimerization complex (Kabeya et al., 2005; Mizushima,
2010). ATG1-ATG13 complex recruits ATG9, a transmembrane
protein ATG9, which is crucial for the initial lipidation of the
phagophoremembrane (Ravikumar et al., 2010). PI3 kinase-beclin-
1 complex depending on the interaction partners can activate or
repress autophagy and also recruit other ATG proteins that are
crucial for the development of the phagosome.UVRAG (Ultra-Violet
Radiation Resistance-Associated Gene) when associated with
AMBRA (Activating molecule in beclin-1-regulated autophagy)
and ATG14 promote autophagy through beclin-1 complex
interaction (Liang et al., 2006). On the other hand, UVRAG
complexed with RUBICON (RUN domain and cysteine rich domain
containing) interaction leads to autophagy repression (Matsunaga
et al., 2009).
Upon autophagy stimulation, beclin-1 is released from Bcl2 at
the endoplasmic reticulum, forms complex with UVRAG/AMBRA,
triggering ATG5-ATG12-ATG16 multimeric complex formation
mediated by ATG7 and ATG10 (Glick et al., 2010). Thus formed
initiating membrane is further incorporated with LC3bII, which is
a cleaved and lipidated product of LC3bI (ATG8) by ATG4 and later
conjugated with phosphotidylethanolamine (PE), irregularly on
both sides of themembrane by ATG9 of the ULK complex (Ghavami
et al., 2012a). During further elongation and autophagosome
formation around the selected cargo for degradation, recruitment
of the membrane from endoplasmic reticulum, mitochondria and
at times even nuclear membrane is well documented (Axe et al.,
2008; Hailey et al., 2010). The completion of autophagosome is
marked by the release of LC3bII from the exterior surface of the
membrane, which is then recycled. Thus, LC3bII is a prominent
marker to monitor autophagic ﬂux (Glick et al., 2010; Gong et al.,
2012). The newly formed autophagosome along with the cargo to
be degraded fuses with lysosome to form autophagolysosome or
autolysosome. The transient formation of amphisome provides the
necessary pH required for the optimal activity of lysosomal
proteases. The fusion of the lysosome with autophagosome is
facilitated by cytoskeletal microtubules by transferring the
autophagosomes to lysosomal proximity for lysosomal membrane
proteins LAMP1/2 and Rab7, member of Rab family GTPases and
[(Fig._1)TD$FIG]
Fig. 1. Summary of basic autophagy signaling events. The key regulator of autophagy, mTOR, is inhibited in the course of multiple metabolically stressful events, including
deprivation of nutrients or growth factors from the extracellularmilieu. mTOR directly phosphorylates ULK1 andmAtg13 and inhibits ULK1 kinase activity, which is essential
for autophagy induction. Thus, autophagy is initiated by the nucleation of an isolationmembrane or phagophore. Thismembrane then elongates and closes on itself to form an
autophagosome. Growth factors, such as insulin, bind tomembrane receptors to activate class I PI3K. This process generates PI(3,4,5)P3, which recruits protein kinase B (PKB/
Akt) and its activator PDK1 (phosphoinositide-dependent kinase 1) to the plasma membrane, resulting in activation of PKB/Akt. Active PKB/Akt indirectly activates mTOR
through inhibition of negative regulators [tuberous sclerosis complex (TSC1/2)] ofmTOR and activating themTOR activator Rheb (Ras homolog enriched in brain). The beclin-
1 complex contributes to the nucleation of the phagophore. Beclin-1 complex is regulated by Bcl-2. Elongation of the phagophore membrane is dependent on the Atg12 and
LC3 conjugation systems. Closure of the autophagosome is dependent on the activity of the LC3-conjugation system. The autophagosomematures by fusing with endosomes
and lysosomes, ﬁnally forming the autolysosome where the cargo degradation occurs. Many stimuli that induce ROS generation also induce autophagy, including nutrient
starvation, mitochondrial toxins, hypoxia, and oxidative stress (Jangamreddy et al., 2013). Recently, it was demonstrated that ROS might induce autophagy through several
distinct mechanisms involving Atg4, catalase, and the mitochondrial electron transport chain (mETC). This leads to both cell-survival and cell-death responses.
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(Atlashkin et al., 2003; Gutierrez et al., 2004b; Lee et al., 2007;
Webb et al., 2004). The stages of autophagy pathway have been
summarized in Fig. 1.
5. Role of mitochondria in autophagy
Mitochondria and their physical dynamics play a vital role at
several stages of autophagy from initial biogenesis of autophago-
some and regulation of the autophagy through beclin-1 to the
autophagy-mediated cell death (Rubinsztein et al., 2012). Recent
studies show that the mitochondrial outer membrane recruits the
autophagy proteins ATG5 and LC3. They are recruited not for the
autophagic removal of mitochondria, mitophagy, but to provide
the anchorage and share the lipid moieties required for the
elongation of the initial phagophore. In the same study, they
illustrate that the cells that lack the mitochondrial protein Mfn2,
which mediate mitochondria anchoring to the endoplasmic
reticulum, do not show such recruitment of ATG5 or LC3 in the
vicinity. This observation suggesting the crucial role of mitochon-
dria and endoplasmic reticulum in the initiation of autophagy
(Hailey et al., 2010). Moreover, mitochondria form tubular
structures by connecting to one another (mitochondrial fusion),
during serum starvation, which also promptly induces autophagy(Twig and Shirihai, 2011). However, the dysfunctional enlarged
senescent mitochondria accumulated during the aging process,
lack the ability to fuse and hamper autophagy (Barnett and Brewer,
2011).
Mitochondria also regulate autophagy through their proteins
Bif1 and Sirt1 by interacting with autophagy initiation complexes
(Kawashima et al., 2011; Takahashi et al., 2007, 2011). Bif1 (also
present in Golgi complex) is mainly involved in endosome
formation, also binds to positive regulator complex of autophagy,
UVRAG and beclin-1, and promotes autophagy (Takahashi et al.,
2007, 2008). Sirt1 promotes autophagy by directly interactingwith
ATG5, ATG7 and LC3/ATG8 (Lee et al., 2008). Other mitochondrial
protein involved in induction of autophagy is smARF, short
mitochondrial form of ARF tumor suppressor protein that induces
cell cycle arrest through p53 dependent pathway, and type I
programmed cell death (apoptosis) (Reef et al., 2006). Unlike its
longer version, smARF induces excessive autophagy-mediated
non-apoptotic cell death that can be counteracted by knockdown
of ATG5 or beclin-1 (Reef et al., 2006).
Mitochondria play a prominent role in autophagy-mediated cell
death by cytochrome c release, either mediated by cleaved
products of ATG4 and ATG5, or through leaked lysosomal protease,
triggered activation of phospholipases and Bax/Bak (Betin and
Lane, 2009; Terman et al., 2010). Fig. 2 outlines mitochondria and
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Fig. 2. Mitochondrial and lysosomal synergistic interplay during aging. Accumulation of non-degradable lipofuscin leads to viscious cyclic damage of mitochondria and
lysosomes mediated by ROS. Apoptosis induced by the proapoptotic protein Bax reduced autophagy by enhancing caspase-mediated cleavage of beclin-1 at D149.
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aging.
6. Autophagy and brain homeostasis
Neurons are differentiated cells with polarized cell-body. Their
viability and function is closely connected to the availability of
trophic factors (include for example neurotrophins like nerve
growth factor (NGF), but also critically depends on active
membrane transport connecting the distant cell body with
dendrites and axons. Neurons, because of their extreme polariza-
tion, size and post-mitotic nature may be particularly sensitive to
the accumulation of aggregated or damaged cytosolic compounds,
or membranes, and depend on autophagy for survival (Tooze and
Schiavo, 2008).
Thus, the beneﬁcial roles of autophagy in nervous system are
mainly associated with maintaining of the normal balance
between the formation and degradation of cellular proteins as
defects in autophagy pathway have been linked to neurodegener-
ative diseases, such as PD (Anglade et al., 1997), AD (Cataldo et al.,
1996), HD (Kegel et al., 2000), and transmissible spongiform
encephalopathy (prion disease) (Liberski et al., 2004). Although
inclusion bodies characterize virtually all neurodegenerative
diseases, they are different in origin and structure, thus causing
disorders with different pathogenesis. In general, both macro-
autophagy and CMA, become markedly less-efﬁcient duringnormal aging, thus contributing directly toward declining of
tissue performance (Martinez-Vicente et al., 2005). In neurode-
generative disorders, it is postulated that incomplete CMA of
cytosolic proteins leads to generation of amyloidogenic fragments
that promote aggregation, which subsequently needs to be
removed by macroautophagy (Cuervo et al., 2004).
Because of bulk removal of intracellular aggregated proteins by
macroautophagy, extensive efforts have been made to understand
whether autophagy is activated to eliminate these aggregated
proteins, or the existence of aggregates is attributed tomalfunction-
ing of the autophagic pathway. On the other hand, there are studies
suggesting that aggregates themselves might actually serve a
neuroprotective function (Arrasate et al., 2004; Rubinsztein, 2006).
Mouse models that accurately model human disease serve as
important research tools to elucidate the mechanisms underlying
in progression of neurodegenerative disorders. Komatsu et al.
(2006) generated mice with tissue-speciﬁc ATG7-knockdown in
the CNS. These mice showed accumulation of inclusion body in
autophagy-deﬁcient neurons with no obvious alteration in
proteasome function. Inclusion bodies were increasing in size
and number with age leading to extensive neuronal loss and dead
within 28 weeks of birth. Their results strongly suggest that
autophagy is essential for the survival of neural cells and that
inadequate level of autophagy is implicated in the pathogenesis
of neurodegenerative disorders involving ubiquitin-containing
inclusion bodies.
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neurodegenerative diseases have been extensively studied over
the past few years. Although these studies have made signiﬁcant
advances in our understanding of the defective steps that lead to
dysfunction of this pathway during aging and age-related
neurodegenerative disorders, most of the molecular components
responsible for diminished autophagic activity associated with
these diseases still remain elusive.
7. Apoptosis and its regulation
Apoptosis, as proposed by the nomenclature committee on cell
death (NCCD), comprise rounding-up of the cell, shrinkage of
pseudopods, decreased cellular volume, chromatin condensation
(pyknosis), nuclear fragmentation (karyorrhexis) along with little
or no ultrastructural reformations of organelles in cytoplasm
followed by plasma membrane blebbing and ingestion by
phagocytes (Los et al., 1999; Rashedi et al., 2007) (Fig. 3).
Proteolytic enzymes with speciﬁcity toward aspartate, and with
cysteine in their active center, called caspases, are well conserved
from early nematodes to the modern vertebrates and are the main
propagators of apoptotic program at the cellular level (Ghavami
et al., 2009b; Stroh et al., 2002). Caspases are present in the
cytoplasm as inactive forms (zymogens), and are activated by
proteolysis (Ghavami et al., 2012c). Caspases have central
functions in mammalian cell apoptosis. The role and indispens-
ability of individual caspases in mammalian cell death have been
best illustrated based on gene-knockout studies (Los et al., 1999).
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The initiator caspases (caspase-8 and caspase-9) are activated ﬁrst
by upstream signals (Los et al., 1995) which later on, activate the
effector caspases (i.e. caspase-3 and caspase-7) (Fuchs and Steller,
2011; Ghavami et al., 2009b). The initiator caspases are activated
by external cell death triggering molecules (for caspase-8: TRAIL,
TNFa, Fas, etc.) (Hashemi et al., 2013; Los et al., 1995) and caspase-
9 activation is triggered by internal stress (starvation and cellular
dysfunction) leading to mitochondrial release of cytochrome c,
which triggers the formation of the apoptosome complex (the
caspase-9 activating complex) (Fuchs and Steller, 2011). Caspase-8
might cleave Bid molecule forming truncated Bid (t-Bid), which
later promotes mitochondrial cytochrome c release and causes
caspase-9 activation (Ghavami et al., 2009a).
Extrinsic apoptotic pathway acts fast (1–2 h under optimal
conditions). Engaged receptors trimerize, recruit adaptor mole-
cules to their death domains and trigger the activation of caspase-
8, and subsequently caspase-3 and -7 that lead to cell death
(Lakhani et al., 2006; Rashedi et al., 2007). In the case of intrinsic
(mitochondrial) apoptotic pathway, a shift in the balance of pro-
apoptotic Bcl2 family members (Bax, Bak, etc.) and anti-apoptotic
member’s toward pro-apoptotic ones, leads to their accumulation
in the outer membrane of mitochondria (Fuchs and Steller, 2011;
Ghavami et al., 2012b), thus leading to the formation of
permeability transition pore (PTP), and subsequent cytochrome
c release (Fig. 3). Cytochrome c and Apaf1 (Apoptotic protease-
activating factor 1) form with pro-caspase-9 in the presence ofintrinsic) or external (extrinsic) stress signals that is activated by binding of ligands
ntrinsic apoptosis pathway might be triggered by p53 upon DNA damage following
ading to release of cytochrome c, which can binds to Apaf1. The cytochrome c/Apaf1
ich promotes caspase-3 activation, eventually leading to cell death. The extrinsic
eptor (TNF-R) family (transmembrane death receptors) by their respective ligands.
ein FADD. Procaspase-8, -10 cleave themselves to form activated caspase-8 or -10.
iate apoptosis. Likewise, there can be cross-talk between the intrinsic and extrinsic
of the intrinsic/mitochondrial apoptotic pathway. The intrinsic pathway is usually
ing cytochrome c release formation of apoptosome and subsequent activation of
er, some of the effector caspases also can activate caspase-8, forming a positive
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caspase-9 activating complex (Adams and Cory, 2002).
Proteolysis is an irreversible process, thus to prevent accidental
triggering of cell death, caspase activation is tightly controlled by
‘inhibitor of apoptosis proteins’ (IAPs) (Ghavami et al., 2008;
Gottfried et al., 2004). While some IAPs can only inhibit active
caspases, others like, i.e. XIAP can also interfere with caspase-
activation process. IAPs are in turn inhibited by Smac/DIABLO
released from themitochondria (Fuchs and Steller, 2011). Caspase-
independent apoptosis can be triggered by Apoptosis-inducing
factor (AIF), which is a mitochondrial ﬂavoprotein oxidoreductase.
This protein is released from mitochondria following apoptotic
signals and translocates to the nucleus, where, it induces
chromatin condensation (Cande et al., 2002).
8. Importance of apoptosis in central- and peripheral nerve
system
Programmed cell death is crucial for normal neural develop-
ment (Miura, 2011). It regulates the number and types of cells in
the developing brain and spinal cord, and plays the key role in
constructing an efﬁcient neuronal network. Under pathologic
conditions, it is also co-responsible for the loss of neurons
associated with neurodegenerative diseases, as well as for
physiologic aging (Tendi et al., 2010). The principal molecular
components of the apoptosis program in neurons include proteins
of the Bcl-2 family, caspases and Apaf1 (Deckwerth et al., 1996;
Hakem et al., 1998; Kuida et al., 1996; Motoyama et al., 1995;
Yakovlev et al., 2001). Proapoptotic BH3-only Bcl2-family proteins
respond to various cell death signals such as DNA damage,
oxidative stress, or limited trophic support, by sequestering their
antiapoptotic counterparts, thus releasing Bax and Bak from
complexes with antiapoptotic Bcl-2 molecules. In turn, Bax and
Bak insert itself into outer mitochondrial membrane contributing
to cytochrome c release. The insertion of Bax and Bak into the outer
mitochondrial membrane largely determines whether the caspase
proteolytic cascade will be unleashed.
Although the data on apoptosis in mammalian neurons mainly
relies on in vitro studies, analysis of animals under experimental
conditions andmouse genetic studies have substantially increased
our understanding of neuronal cell death regulation. Mice lacking
Apaf1 died before birth with enlarged brains due to impaired
apoptosis during neuronal development (Cecconi et al., 1998;
Yoshida et al., 1998). However, Apaf1 is not required for apoptosis of
postmitotic neurons (Honarpour et al., 2000). Motoyama and
colleagues demonstrated that disruption of the antiapoptotic bcl-
xL gene is lethal at day 13 of gestation (Motoyama et al., 1995).
Further investigation on Bcl-xL-deﬁcient embryos revealed exten-
sive apoptotic cell death in postmitotic immature neurons of the
developing spinal cord, brainstem, anddorsal root ganglia and in the
hematopoetic system (Los et al., 2002). On the other hand, deletion
of pro-apoptotic gene bax in mice largely eliminated neuronal cell
death within the CNS during development (Hellwig et al., 2011;
White et al., 1998). Furthermore, postnatal Bax deﬁciency leads to
prolong cerebellar neurogenesis and accelerates medulloblastoma
formation (Garcia et al., 2012). Interestingly, concomitant bax
deﬁciency protects bcl-xL-deﬁcient embryos from excess neuronal
apoptosis, although it did not rescue the embryonic lethality
associated with bcl-xL deﬁciency (Shindler et al., 1997). More
recently, Ghosh and colleagues (Ghosh et al., 2011) showed reduced
apoptotic cell death in the developing nervous system of pro-
apoptoticHarakiri (Hrk) deﬁcientmice,while Hrk deﬁciency didnot
signiﬁcantly attenuate the massive apoptosis seen in the Bcl-xL-
deﬁcient embryos’ nervous system. These observations suggest the
possible role for other BH3-onlymolecules, alone or in combination,
in regulation of Bax activation in developing neurons.The role of caspases in neural development has been examined
by several groups. Johnson and colleagues demonstrated that DNA
damage increased caspase activity in both cultured embryonic
telencephalic and postnatal cortical neurons in a p53-dependent
manner (Johnson et al., 1999). Since in some cases, p53-mediated
neuronal cell death may also occur via caspases-independent
pathways, they conclude that the relative importance of caspase
activation in neurons depends on the developmental status of the
cell and the speciﬁc nature of the death stimulus (Holler et al.,
2000). Role of the caspases in neural development has been studied
using animal models. Gene deletion of both caspase-3 (Cho et al.,
2009) and caspase-9 (Mughal et al., 2012) in mice resulted in
defects within the CNS that include neuronal hyperplasia of the
cortex, cerebellum, striatum, hippocampus, and retina, and
neuronal disorganization.
9. Alzheimer’s disease
AD ﬁrst described almost 100 years ago by Alois Alzheimer, as a
progressive, degenerative disorder of the brain. In industrialized
countries approximately 7% of people older than 65 years and
about 40% of people older than 80 years are affected (Glass et al.,
2010). The estimated risk for developing AD is about 20% for
women and 10% for men for age above 65 (Seshadri and Wolf,
2007). The pathology of AD is characterized by an accumulation of
misfolded proteins, inﬂammatory changes and oxidative damage.
This result in region-speciﬁc loss of synaptic contacts and neuronal
cell death (Querfurth and LaFerla, 2010).
Nowadays, around 25–30 million people worldwide are
diagnosed with AD and estimations predict a threefold increase
by the year 2040 (Minati et al., 2009). AD may have both sporadic
and familial etiology. The sporadic form accounts for about 95% of
the cases and have a late onset at about age 65, while early onset in
some cases in the familial form have been reported (Martin, 2010;
Minati et al., 2009). In the familial form, mutations in the genes
encoding amyloid precursor protein (APP), presenilin-1 (PSEN1)
and presenilin-2 (PSEN2) are associated with AD (Minati et al.,
2009). APP is a transmembrane protein that affects b-catenin,
anchoring the protein to the actin cytoskeleton and plays an
important role in cell-cell adhesion as well as in Wnt signaling
(Chen and Bodles, 2007; Nizzari et al., 2007). Upon cleavage of APP
through g-secretase-mediated processes by PSEN1 and PSEN2, the
neurotoxic peptide amyloid-b (Ab) is formed (Nizzari et al., 2007;
Sotthibundhu et al., 2008; Vila and Przedborski, 2003). Abnormal
levels of extracellular Ab-peptides are found as plaques in patients
diagnosed with AD as well as abnormal levels of intracellular
neuroﬁbrillary tangles of aggregated proteins containing hyper-
phosphorylated tau (Martin, 2010). In sporadic cases of AD,
apolipoprotein E (ApoE) may modify the g-secretase activity,
although the deﬁnitive pathway is yet to be determined.
Furthermore, indications of variations in the genes encoding
insulin-degrading enzyme (IDE) and ubiquilin-1 (UBQLN1),
involved in Ab degradation and intracellular trafﬁcking of APP
respectively, have been reported (Minati et al., 2009).
Epigeneticmechanismsmay also play a role in AD pathogenesis
(Day and Sweatt, 2011). Studies on human postmortem brain
samples and peripheral leukocytes, as well as transgenic animal
models, have identiﬁed many links between aging, AD and
epigenetic deregulations (Chouliaras et al., 2011), including
abnormal DNA methylation and histone modiﬁcations (Day and
Sweatt, 2011). Though it is still unclear whether these deregula-
tions represent a cause or a consequence of the disease. Twin
studies support the notion that epigenetic mechanisms modulate
AD risk (Chouliaras et al., 2011). In fact, pharmacological inhibition
of DNA methylation in the hippocampus after a learning task
infringes memory consolidation in mice (Day and Sweatt, 2011).
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learning and memory in a mouse model of AD and increases
learning-related gene expression in aged wild-type mice (Kim
et al., 2007) suggesting epigenetic regulation of learning and
memory in health and disease (Huang and Mucke, 2012).
Various environmental exposures can alter an individual’s risk
of developing AD, such as nutrition, exposure to a Mediterranean
diet, ﬁsh and high omega-3 diets, cigarette smoking, head trauma,
infections, systemic inﬂammation, and metal and pesticide
exposure (Chouliaras et al., 2011). In addition, psychosocial factors
such as education, social network, leisure activities and physical
activity, chronic stress, and depression may modify the risk of AD
(Ganguli and Kukull, 2010; Qiu et al., 2007). On the other hand,
somatic factors related to environmental exposures, such as blood
pressure, obesity, diabetes mellitus, cardio- and cerebrovascular
diseases, and hyperlipidemia, are also implicated in AD etiology
(Ganguli and Kukull, 2010; Qiu et al., 2007). Recent studies have
reported a strong correlation between type 2 diabetes and AD
(Granic et al., 2009), as type 2 diabetes with hyperinsulinemia
increases the risk of AD in elderly people.
10. Parkinson’s disease
PD initially described in 1817 by James Parkinson in his ‘‘Essay
on the Shaking Palsy’’, whereas the term ‘‘Parkinson’s disease’’ was
actually coined by J. M. Charcout, over 60 years later. PD is a[(Fig._4)TD$FIG]Fig. 4. Role of genetic factors and their interplaywith environmental factors in PD. In dopa
role in the etiology of PD, such as PINK1, LRRK2. Oxidative stress and other cellular-stress
products such as Parkin, DJ-1 or PINK 1. This may lead to the interference with the functiprogressive neurological incurable disorder with no preventative
nor effective long-term treatment strategies (Habibi et al., 2011). It
is the second most common neurodegenerative disease after AD.
Currently, about 2% of the population over the age of 60, and 0.3% of
the general population is affected (Martin, 2010; Samii et al., 2004).
The patients suffering from PD display symptoms of motoric
instabilities with resting tremor at a typical frequency of 3–5 Hz as
the ﬁrst symptom in 70% of the cases. Other clinical motoric
symptoms are rigidity, bradykinesia and postural instability. Non-
motoric symptoms include cognitive impairment, depression and
sleep disorders (Jankovic, 2008).
The etiology of PD remains uncertain even though it is one of
the most common progressive movement disorder in the elderly
(Huang and Halliday, 2012). Genetic, environmental risk factors
and their interaction play a major role in PD (Fig. 4). Recently,
several genes that are directly related to some cases of Parkinson’s
disease have been discovered. In 1997 a missense mutation in the
alpha-synuclein (a-syn) gene was found to be associated with the
disease in some families with autosomal dominant mode of
inheritance of parkinsonism (Polymeropoulos et al., 1997).
Although 90% of PD cases are sporadic, the study of genetic
defects has provided great progress in the understanding of PD
molecular mechanisms (Ali et al., 2011). Mutations in the leucine-
rich repeat kinase 2 (LRRK2, PARK8) are the most frequent known
cause of familial autosomal dominant PD (Zimprich et al., 2004).
More recently a common genetic variant (LRRK2 G2385R) haveminergic neurons oxidative stress can occur due to defects of genes known to play a
stimulimay lead to neuronal cell death by disrupting the function of PD related gene
on of mitochondria or induction of inﬂammatory processes within neuronal tissues.
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LRRK2 Gly2385Arg another variant have also been identiﬁed in
2006. The presence of genetic defects in the sporadic cases of PD as
well as the high variable onset age and phenotypic variation in the
inherited PD form emphasizes the crucial role of genetic defects in
the development of PD (Ali et al., 2011).
Although the clear involvement of environment in PD remains
debated, many risk factors have been identiﬁed and are directly or
indirectly related to the disease. In the 1980s, it was found that
exposure to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine), caused PD-like symptoms. Paraquat and rotenone, in
addition to other environmental toxins, and other factors that
cause mitochondrial dysfunction have been reported as high risk
factors for PD (Habibi et al., 2011). Various studies suggest that PD
neurodegeneration is the result of a gene environment complex
affecting various stages of progressive mechanisms leading to the
neuronal death in PD (see Fig. 4) (Ali et al., 2011).
11. Huntington’s disease
HD is a neurodegenerative disorder affecting parts of the brain,
which regulates the movements, mainly the basal ganglia, causing
the characteristics of uncontrolled movements called chorea
(Walker, 2007). Other symptoms of HD are dystonia, incoordina-
tion, cognitive impairment and behavioral difﬁculties. The preva-
lence peak in white populations amounts to about 5–7 cases per
100 000, except from some rural areas of inbreed with higher
frequency. HD is an autosomal dominant disorder, caused by a
mutation in the Huntingtin gene located on chromosome 4, with a
typical onset at age 35–44. The gene contains a multiple repeat of
CAG nucleotides encoding glutamine. More than 35 repeats are
associated with the disease and the age of onset is lower with
increasing number of repeats. The role of Huntingtin protein (htt)
is currently unclear. Huntingtin may have anti-apoptotic proper-
ties of the protein as well as the control of brain-derived
neurotrophic factor production, vesicular transport, neuronal gene
transcription and synaptic transmission (Cattaneo et al., 2005). The
mechanism of the neurodegenerative process in HD is not fully
deﬁned. However, one explanation involves the cleavage of the
mutated protein. Created n such way fragments with high poly-
glutamine (pQ) content may form aggregates through hydrogen
bonds, and mechanically stop transmission of neurotransmitters
between neurons (Rubinsztein and Carmichael, 2004). Another
explanation of the cytotoxicity is the binding betweenmutated htt
aggregates with the small guanine nucleotide-binding protein
Rhes, located in the striatum, and inducing sumoylation of the
aggregates (Subramaniam et al., 2009). Furthermore, suggestions
of pathogenic mechanisms include excitotoxicity (the process of
neuronal damage by neurotransmitter, through overstimulation of
receptors), mitochondrial dysfunction, increased activity of
caspases, autophagy, proteolytic cleavage by proteasomes and
aspartyl proteases, and abnormal histone modiﬁcations (Sadri-
Vakili and Cha, 2006). The available treatment includes, i.e.
amantadine, remacemide, levetiracetam and tetrabenazine. The
pharmacologic intervention is able to reduce the symptoms of HD,
but there are currently no drugs to stop or reverse the progress of
the disease (Walker, 2007).
12. Amyotrophic lateral sclerosis
ALS is caused by the degeneration of motor neurons in the
central nervous system and is characterized by muscle weakness
and atrophy, spasticity, paralysis and in some cases dementia
(Martin, 2011). With a typical onset between 35 and 50 and a life
expectancy after diagnosis of 3–5 years, the disease is affecting
about 2 per 100 000 each year (Blackhall, 2012). The majority,about 90–95%, of the patients has no family history of ALS and the
cause of this sporadic form is unclear. In the familial form,
mutations in the superoxide dismutase 1 (SOD1) gene are themost
common cause of ALS (Carri and Cozzolino, 2011). SOD1 is an
antioxidant enzyme protecting neurons from free superoxide
radicals and can, in the mutated form, stimulate protein
aggregation that might lead to apoptosis. Mutant forms of the
protein TDP-43 encoded by the TARDBP gene (Sreedharan et al.,
2008), as well as mutations in the FUS gene encoding an RNA
binding protein (Vance et al., 2009), are also among the genes
associated with familial ALS (Martin, 2011). The mechanism of the
pathology is unclear; however, suggestions include mitochondrial
pathobiology (Martin, 2011), lactate dyscrasia (Vadakkadath
Meethal and Atwood, 2012), immune system alterations (Manto-
vani et al., 2009) and protein aggregation (Shaw, 2005). Currently,
riluzole is the only therapy available on the market, however, the
median prolonged life expectancy is only 2–3months (Miller et al.,
2012).
13. Neuroinﬂammation in neurodegenerative diseases
Inﬂammation is a self-defensive reaction against various
pathogenic stimuli that helps the organism respond to pathogens
or irritation. Nevertheless, inﬂammation when chronically im-
paired may become a harmful self-damaging process that can
cause serious damage to host’s own tissue.While the CNS has been
known as an immune privileged organ, increasing evidence
support the involvement of chronic inﬂammation in various
neurodegenerative disorders including AD, PD and ALS (Banati
et al., 1998; McGeer et al., 1988; Raine, 1994). In this context,
chronic inﬂammation-mediated tissue damage can be particularly
harmful to the brain, since neurons are generally irreplaceable.
13.1. General dynamics of neuroinﬂammation in
neurodegenerative diseases
Neuroinﬂammation is a term describing cellular and molecular
processes, which encompasses activation of microglia and astro-
cytes and inﬁltration of peripheral immune cells. In the central
nervous system, microglia, antigen presenting brain immune cells
(or macrophages), are the innate immune components of the CNS.
Under normal condition, they play major role in the inﬂammatory
process and insure the CNS parenchymal integrity. Activated
microglia at the site of inﬂammation change their morphology,
express increased levels of MHC antigens and become phagocytic
(Hayes et al., 1987). They release inﬂammatory cytokines that
amplify the inﬂammatory response by activating and recruiting
other cells to the brain lesion. On the other hand, uncontrolled
activation of microglia may directly be toxic to neurons. The
toxicity has been observed in numerous neurodegenerative
disorders, and it is mediated by releasing various toxic substances
including inﬂammatory cytokines (IL-1b, TNF-a, IL-6), NO, PGE,
and superoxide. In addition, activated microglia has the ability to
phagocyte not only damaged cell debris but also neighboring intact
cells, thus causing neurodegeneration. Though microglia can have
both a protective and a devastating role, its activation and
functions in NDD plays a more signiﬁcant role in mediating the
diseases than in protecting neurons, among them AD, PD, ALS
(Banati et al., 1998; Dickson, 1997; Raine, 1994).
13.2. Alzheimer’s diseases and neuroinﬂammation
The suggestion that inﬂammation may participate in AD ﬁrst
came up more than two decades ago. Many investigators have
concluded that neuroinﬂammation contributes to neuronal
damage in the brain during AD (Akiyama et al., 2000). In fact,
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proximity to senile plaques within the AD brain. In this activated
state, microglia produces various pro-inﬂammatory cytokines and
other immune mediators that create a neurotoxic environment
(proteolytic enzymes, excitatory amino acids, quinolinic acid,
complement proteins, reactive oxygen intermediates, and nitric
oxide (Cassarino et al., 1997; Chao et al., 1992; Gao et al., 2002;
McGuire et al., 2001) leading to disease progression (Akiyama et al.,
2000; Wyss-Coray, 2006). For instance, the ratio of the pro-
inﬂammatory cytokine IL-1 to the anti-inﬂammatory cytokine IL-
10 is greatly elevated in the serum of AD patients, resulting in a
chronic neuroinﬂammation. In addition, the accumulating loss of
neurons that characterizes AD further contributes to generation of
debris and keeps microglia in an indeﬁnitely activated state that
further amplify its neuro-toxic production. Ab itself may act as a
pro-inﬂammatory agent causing the activation of many of the
inﬂammatory components. The involvement of neuroinﬂamma-
tion in AD has further been supported by the ﬁndings that patients
who took non-steroidal anti-inﬂammatory drugs had a lower risk
of AD than those who did not.
13.3. Parkinson’s disease and neuroinﬂammation
PD is also recognized to have an inﬂammatory component (Qin
et al., 2007). As seen in AD, the brain of PD patient is also
characterized by an upregulation of HLA-DR antigens and the
presence of HLA-DR-immunopositive and highly reactive micro-
glia (McGeer et al., 1988). Activated microglia-mediated dopami-
nergic neuronal degeneration has been demonstrated using animal
models (Gao et al., 2002) showing that microglia plays a central
role in rotenone-induced dopaminergic neuronal degeneration.
Moreover other studies demonstrated that the inhibition of
microglial activation prevents dopaminergic neuronal loss in
MPTP-treated mice (Wu et al., 2002). In addition, non-steroidal
anti-inﬂammatory drugs reduce PD (Wahner et al., 2007)
conﬁrming the involvement of innate immunity in PD. Adaptive
immunity is also involved in PD (Huang and Halliday, 2012). In PD
brain the BBB (blood brain barrier) is disrupted due to activated
microglia and monocytes (Stone et al., 2009) and IgG, has been
shown bound to dopamine neurons in the substantia nigra of
idiopathic and familial PD patients, but not in age-matched
controls (Orr et al., 2005).
13.4. Amyotrophic lateral sclerosis and neuroinﬂammation
Inﬂammation in ALS is characterized by gliosis and the
accumulation of large numbers of activated microglia and
astrocytes. Activation of glia in ALS is associated with an elevated
production of cytotoxic molecules such as ROS, inﬂammatory
mediators such as COX-2, and proinﬂammatory cytokines such as
IL-1b, TNF-a, and IL-6 (McGeer and McGeer, 2002). In addition,
major histocompatibility complex molecules and complement
receptors are highly expressed by reactivemicroglia in the primary
motor cortex and in the anterior horn of the spinal cords of ALS
patients (McGeer and McGeer, 2002).
Studies supporting a detrimental role for activated glial cells in
ALS include the ﬁnding that the chronic administration of
lipopolysaccharide or the deletion of the receptor for the
chemokine, fractalkine, is associated with a robust astrocytosis
and microgliosis and an exacerbated ALS-like phenotype in
mutant SOD1 Tg mice (Cardona et al., 2006). Moreover, once
activated, astrocytes become capable of killing previously healthy
neighboringMNs (Cassina et al., 2002). After activation, glial cells
start producing a host of toxic molecules (Kreutzberg, 1996)
which in turn mediate the glial harmful action on neighboring
neurons.14. Autpophagy hyperactivation or failure associated with
neuronal cell death
In neurodegenerative disorders impairment at distinct steps of
autophagy including autophagosome formation, cargo recognition,
transport, autophagosome/lysosome fusion, autophagosome
clearance and cargo degradation, conducts to the buildup of
damaged organelles altered or pathogenic protein, while defeating
autophagy’s crucial prosurvival and antiapoptotic effects on
neurons (Fig. 5). The differences in the location of defects within
the autophagy pathway and their molecular basis inﬂuence the
pattern and pace of neuronal cell death in the various neurological
disorders.
Although proposed to be a primary or irreversible death trigger,
autophagy is now widely considered as both a vital homeostatic
mechanism in healthy neuronal cells as described in previous
paragraphs as well as a cytoprotective response when further
induced in chronic neurodegenerative disorders (Marino et al.,
2011; Moreau et al., 2010; Nixon and Yang, 2012). This protective
effect is not simply a function of autophagy liberating fuels for
cells, but appears to be related to decrease in the amount of
mitochondria (because of mitophagy). This, in turn, results in less
release of toxic molecules like cytochrome c from mitochondria in
response to proapoptotic insults. Koike and colleagues reported in
vivo evidence of neuronal cell death requiring autophagy in the
mammalian brain.
Although autophagy is mostly neuroprotective, can it also be
deleterious? Although expression autophagic cell death (ACD)
suggests that cell death is executed by autophagy, recent data from
the Kroemer laboratory (Shen et al., 2011) using high-throughput
chemical screens failed to demonstrate that any of these
compounds killed cells via autophagy. The results of such studies
could be inﬂuenced by a possible role of ATG genes in other
functions involved in cell death unrelated to autophagy. And some
scientist argue that rapidly dividing mammalian cells as cancer
cells are not the most likely situation for ﬁnding pure ACD (Clarke
and Puyal, 2012). However, ACD can be now deﬁned on the basis of
the following set of criteria: (i) ACD must be a distinct death
mechanism, independent of apoptosis or necrosis. Thus, situations
in which autophagy triggers apoptosis or necrosis, or occurs in
parallel with them, are excluded even when the autophagy has
been clearly shown to promote cell death (ii) there is an increase in
autophagic ﬂux, and not just an increase in the autophagic
markers, in the dying cells; (iii) suppression of autophagy via either
pharmacological inhibitors or genetic approaches is able to rescue
or prevent cell death. (iv) autophagy must ‘‘. . .be itself responsible
for the ﬁnal dismantling of cellular content and hence execute a
lethal pathway’’ (Shen et al., 2012). Debate continues as towhether
a deﬁnition of ACD should include this last criterion (Clarke and
Puyal, 2012). In light of this new deﬁnition, in mammalian cells,
however, ACD is uncommon. It is not entirely clear that autophagy
is sufﬁcient to execute death without help from apoptosis or
necrosis (Nixon and Yang, 2012). In some cases, autophagic
vacuole proliferation occurs in the context of cell death executed
by caspases and may facilitate execution but is not essential for
death.
Autophagy inhibition by 3-methyl adenine (3MA) has been
used to implicate autophagy in cell death execution by showing
blocked or delayed cell death after this treatment. Although the
interpretation of protection via autophagy inhibition should be
qualiﬁed because this inhibitor has a dual role in modulation of
autophagy via different temporal patterns of inhibition on class I
and class III phosophoinositide 3-kinase (Wu et al., 2010). Also, in
most of these cases, cytoprotection is not absolute and death
ﬁnally results via cytochrome c release and caspase cascade
activation indicating that an apoptotic pathway may be operating
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Fig. 5. Distinct steps of the autophagic pathway can be altered in a variety of neurodegenerative disorders and possible links to neuronal cell death. The different alterations
linked to neurodegeneration affecting autophagic ﬂux including reduced autophagy induction or enhanced autophagy repression; altered cargo recognition; inefﬁcient
autophagosome/lysosome fusion; inefﬁcient autophagosome clearance; and inefﬁcient degradation of the autophagic cargo in lysosomes. Examples of neurodegenerative
diseases for which alteration in each step are shown. The autophagy alteration may promote neuronal cell death via two possible mechanisms: (1) impairment of cargo
degradation in lysosome leading to lysosomal membrane permeabilization (LMP) and cathepsin release into cytosol, thereby inducing either apoptotic or necrotic cell death;
(2) failure in mitophagy resulting in accumulation of damaged mitochondria and mitochondrial membrane permeability (MMP) leading to cytochrome c release and
apoptotic cell death AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CMT, Charcot–Marie–Tooth disease; FTD, fronto-temporal dementia; HD, Huntington’s
disease; LSDs, lysosomal storage disorders; PD, Parkinson’s disease; SCAs, spino-cerebelar ataxias; SMA, spinal muscular atrophy; SP, spastic paraplegia.
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Furthermore, cathepsin inhibition also blocks or delays cell death
in many models, further supporting the idea that lysosomal
destabilization and cathepsin release ﬁnally triggers apoptosis
(Canu et al., 2005; Kaasik et al., 2005; Uchiyama, 2001).
Autophagy induction is frequently associated by up-regulated
hydrolase synthesis and increased lysosome biogenesis (Settembre
et al., 2011). Under circumstances in which lysosomes are
destabilized or their function is compromised, it is more likely
that autophagy inhibitors attenuate autophagic stress on com-
promised lysosomes by decreasing delivery of autophagic cargo
rather than by attenuating an overaggressive auto cannibalistic
process. Indeed, healthy neurons in culture seem to tolerate robust
autophagy induction (Lee et al., 2011) expect when lysosomal
function is also impaired. In situation which prevent of autophagy
is neuroprotective, counteraction of lysosome destabilization
could be more suitable to the mechanism of cytoprotection than
is the blockade of authentic ACD.
As described above, there has been skepticism that mammalian
cells can die through excessive autophagy, however recently Lamy
et al. provide support for the idea that deregulated autophagy
could result in cellular auto destruction in multiple myeloma.
These cells utilize caspase 10 to restrain autophagy and undergoes
ACD upon its inhibition or removal (Lamy et al., 2013). In contrast
to autophagy hyperactivation, autophagy failure is commonly
linked to a lysosome dependent form of cell death (Boya and
Kroemer, 2008) which is relevant to the loss of neurons in various
neurodegenerative diseases. Loss of function of lysosomal enzymes
or structural proteins leads to defects at autolysosomal stages of
autophagy. A neuronal cell death involving autophagy is seen in
lysosomal storage disorders owing to these defects, although the
evidence is mostly in vitro.
Depletion of factors critical for autophagy induction or
autophagosome formation such as Atg5, Atg7 or FIP200, inducesneuronal cell death and cytoplasmic accumulation of organelles or
ubiquitinated proteins (Komatsu et al., 2006; Liang et al., 2010). In
neurodegenerative disorders impairment at distinct steps of
autophagy, can trigger neuronal cell death in several ways
(Fig. 5). When, autophagosome clearance and cargo degradation
steps are compromised, autolysosomes/lysosomes accumulate
mutant and oxidized proteins, protein oligomers and aggregates,
damaged organelles, and other incompletely digested products.
Such conditions increase the permeability of lysosomal mem-
branes causing hydrolases release into the cytoplasm (Kroemer
and Jaattela, 2005). Both exogenous (Erdal et al., 2005) and
endogenous factors are able to disrupt lysosomal membrane
integrity directly and induce rapid lysosome-dependent cell death
(Boya and Kroemer, 2008; Johansson et al., 2010; Repnik et al.,
2012). Endogenous factors able to induce lysosomal membrane
permeabilization (LMP) includes a few proteins/peptides impli-
cated in AD, such as Ab and ApoE, calpains, ceramide, certain
caspases, oxidized lipids or lipoproteins, reactive oxygen species
(ROS), and sphingosine. Factors that cause disruption of lysosomal
membranes are likely to induce necrosis during which released
lysosomal hydrolases participate as both a trigger and as
executioners along with caspases that are activated by cathep-
sin-mediated cleavage (Hartmann et al., 2000; Werneburg et al.,
2004). Slower lysosomal cathepsins release may ﬁrst activate
apoptotic cascades via cytochrome c release from mitochondria,
degradation of antiapoptotic Bcl-2 family, and activation of Bax
that releases mitochondrial AIF and can also induce LMP. In a
pathological situation in which distinct steps of autophagy are
impaired, the resultant increase in numbers of damaged mito-
chondria can trigger apoptosis through the intrinsic pathway and
via ROS generation that oxidizes membrane lipids and destabilizes
the lysosomemembrane. Reduced autophagic elimination of other
proapoptotic factors, such as activated caspases, may also
accelerate apoptosis under these conditions (Yang et al., 2008).
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Below, we discuss various neurodegenerative disorders
including Alzheimer’s, Parkinson’s, Huntington’s, and amyotrophic
lateral sclerosis that are associated with impairment in the
different stages of autophagy (Fig. 5).
15.1. Alzheimer’s diseases – disturbed autophagy as
a contributing factor
One hypothesis on the etiology of AD is based on the
accumulation of damaged mitochondria in the neurons. Accord-
ingly, translocation of misfolded proteins into the mitochondrial
membrane leads to the disruption of oxidative phosphorylation
(Rhein et al., 2009) and subsequent autophagy activation (Smaili
et al., 2011). Lysosomes are essential components of autophagy
while autophagic degradation of damaged mitochondria is an
important factor in quality control of mitochondria (Gusdon et al.,
2012). Thus, a decline in autophagy efﬁciency during aging
(Rubinsztein et al., 2011; Taylor and Dillin, 2011) leads to
accumulation of Ab and a-syn oligomers in the mitochondrial
membrane and the release of cytochrome c. This event can trigger
the caspase cascade that results in extreme cell death and
neurodegeneration (Hashimoto et al., 2003). In line with this
notion is the observation that Zinc ion (Zn2+) supplementation
improved mitochondrial function and ameliorated hippocampal
Ab and tau pathogenic signs in a mouse model of AD. Notably,
dietary Zn2+ supplementation reduced intraneuronal Ab, tau
pathology, and prevents mitochondrial deﬁcits. Zinc chelation,
on the other hand appears to have toxic effect, at least in some cell
types (Hashemi et al., 2007). This treatment also restored BDNF
levels and prevented hippocampal-dependent cognitive deﬁcits.
Furthermore, detection of massive neuronal accumulation of
autophagosomes in dystrophic and degenerating neurites, pointedTable 1
Macroautophagy in proteopathic neurodegenerative diseases and their therapeutic mo
Proteopathic
neurodegenerative
disorders
Macroautophagy Chapero
Alzheimer’s disease Macroautophagy is transcriptionally
up-regulated (Lipinski et al., 2010)
Autophagosome maturation is
impaired (Yu et al., 2005)
Macroautophagy is inhibited by
mutated presinilin-1 in a familial form
of AD (Cataldo et al., 2004)
CMA de
(RCAN1
CMA de
Parkinson’s disease Macroautophagy degrades wild-type
and mutated a-syn (Vogiatzi et al.,
2008)
CMA de
et al., 20
CMA is
(Cuervo
CMA act
patient
Huntington’s disease Macroautophagy is debilitated to
cargo recognition (Martinez-Vicente
et al., 2010)
Macroautophagy degrades Htt43Q
(Carra et al., 2008)
Macroautophagy is impaired in early
stages of HD (Koga et al., 2011)
CMA de
2010)
CMA is
(Koga e
Amyotrophic lateral
sclerosis
Macroautophagy degrades mutated
and wild type SOD1 (Hetz et al., 2009;
Kabuta et al., 2006)
Macroautophagy degrades TDP-43
(Johnson et al., 2010)
Macroautophagy is induced by
mutated SOD1 (Crippa et al., 2010b;
Li et al., 2008)
No avaito deﬁcit in axonal transport as a possible pathologic reason for AD
(Silva et al., 2011).
Mobile mitochondria can halt in regions with high metabolic
demands (Sheng and Cai, 2012), thus aberrant axonal transport
could inﬂuence effective function of mitochondria. On the other
hand, an in vitro study has reported an association between
inhibition of lysosomal proteolysis and disturbed axonal transport
in cortical neurons. The observed neuritic dystrophy was reversed
by enhancing lysosomal proteolysis (Lee et al., 2011). This
connection maybe exerted via microtubule-associated protein
1S (MAP1S). MAP1S interacts with LC3 (autophagosome-associat-
ed light chain 3), LRPPRC (mitochondrion-associated leucine-rich
PPR-motif containing protein) aswell asmicrotubules, and thereby
may affect integration of components of autophagosomes (Xie
et al., 2011). We have brieﬂy summarized the role of macro-
autophagy in AD in Table 1.
15.2. Parkinson’s disease – autophagy as possible protective factor
Accumulation of a-syn-containing Lewy bodies in substantia
nigra neurons is the hallmark of PD (Mizuno et al., 2008). Recently
scientists have focused more on the production, function and
degradation of a-syn oligomers (Sulzer, 2010; Vekrellis et al.,
2011). Wild-type a-syn is degraded by both UPS and macro-
autophagy, especially via CMA (Cuervo et al., 2004), while its
mutant form gain a toxic function and binds to and blocks CMA
receptors (Cuervo et al., 2004). Reduced CMA function then causes
accumulation of more aggregated proteins and worsening of the
situation (Alvarez-Erviti et al., 2010; Cuervo et al., 2004). Although
mutant a-syn is partly degraded through macroautophagy, it also
aggregates and produces oligomers, as overexpressed wild type
a-syn and dopamine modiﬁed a-syn do (Sulzer, 2010). a-Syn
oligomers seem to interact with organelle lipid membranes
(Sulzer, 2010) and interfere with their normal function leadingdulators.
n-mediated autophagy Potential therapeutic modulators
grades regulator of calcineurin-1
) (Liu et al., 2009)
grades Tau proteins (Wang, 2009)
Raprmycin (Mendelsohn and Larrick,
2011; Spilman et al., 2010)
Resveratrol (Kim et al., 2007; Vingtdeux
et al., 2011)
Nicotinamide (Liu et al., 2013a)
Latrepirdine (Steele and Gandy, 2013)
grades wild-type a-syn (Cuervo
04; Vogiatzi et al., 2008)
inhibited by mutated a-syn
et al., 2004)
ivity is reduced in the brain of PD
(Alvarez-Erviti et al., 2010)
Rapamycin (Dehay et al., 2010;
Mendelsohn and Larrick, 2011)
Trehalose (Sarkar et al., 2007)
Kaempferol (Filomeni et al., 2012)
Resveratrol (Wu et al., 2011)
Isorhynchophylline (Lu et al., 2012)
grades mutated Htt (Bauer et al.,
up regulated in early stage of HD
t al., 2011)
Trehalose (Sarkar et al., 2007)
Rapamycin (Mendelsohn and Larrick,
2011; Ravikumar et al., 2002)
Rilmenidine (Rose et al., 2010)
lable data Litium (Fornai et al., 2008)
Resveratrol (Kim et al., 2007)
Trehalose (Gomes et al., 2010)
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Vekrellis et al., 2011) as well as lysosomal and proteosomal
dysfunction (Sulzer, 2010).
A number of studies have suggested the attenuation of
macroautophagy and UPS function (Dehay et al., 2010) or aberrant
and incomplete progress in degradation pathways (Cuervo et al.,
2004) as important initiators of PD (Dehay et al., 2010). Besides,
numerous in vitro studies have demonstrated that induction of
autophagy with different types of compounds such as trehalose
(Dehay et al., 2010; Mendelsohn and Larrick, 2011), kaempferol
(Filomeni et al., 2012), Isorhynchophylline (Lu et al., 2012) and
resveratrol (Wu et al., 2011), results in improvements in the
molecular traits of PD.
The other concept of PD etiology returns to the mitochondrial
dysfunction mediated by protein products of the mutant genes
that are recognized in the hereditary PD. PINK1-parkin pathway is
suggested as a mitochondrial morphology controller. It regulates
mitochondrial function and its aberrant activity could induce
mitophagy (Lazarou et al., 2012; Narendra et al., 2008). Another
function attributed to PINK1 is its interaction with beclin-1 that
results in the elevation of basal and starvation-induced autophagy.
Furthermore, mutations in DJ-1 that cause loss of function of this
gene lead to mitochondrial dysfunction, elevated levels of ROS and
decreased lysosomal-autophagic degradation (Krebiehl et al.,
2010). These events result in the accumulation of damaged
mitochondria (Krebiehl et al., 2010). Aberrant accumulation of
autophagosomes in PD, that used to be interpreted as an abnormal
induction of autophagy is alternatively suggested to be due to
defective autophagic clearance. This defect has been hypothesized
as a consequence of alterations in the microtubule network driven
by mitochondrial dysfunction (Arduino et al., 2013). Thus, speciﬁc
defects in selective autophagy or cargo recognition may be
sufﬁcient to cause PD (Narendra et al., 2008). Taken all data
together, activation of autophagy seems to be a good strategy to
ﬁght progression in PD. Table 1 brieﬂy summarized the role of
macroautophagy in PD.
15.3. Huntington’s disease – potential pro-survival effect of
autophagy
Neuronal intranuclear inclusions were initially offered as the
molecular pathogenic cause of HD (Davies et al., 1998). Further
cellular studies however showed that these inclusion bodies could
ameliorate survival of the rat embryonic striatal neurons (Arrasate
et al., 2004). Now it has been revealed that mutant Htt when inside
the inclusion bodies, and as aggregated forms are less toxic than
the soluble form of the protein (Zuccato et al., 2010).
Another hypothesis on the cause of HD suggests that
mitochondrial defects may play a central role (Pickrell et al.,
2011). Investigations on the immortalized cell lines from HD
patients have shown that the presence of one HD allele results in
the mitochondrial membrane hyperpolarization and increased
susceptibility to apoptosis. Addition of another HD allele to these
cells increased the number of cells that contained autophagic
vacuoles with more cannibalistic activity (Mormone et al., 2006).
These ﬁndings alongwith results of other studies (Ravikumar et al.,
2006), suggest that mitophagy eliminates damaged mitochondria
and thus prevents the release of cytochrome c and other
proapoptotic proteins, leading to the inhibition of cell death and
neurodegeneration.
Recent ﬁndings have led to the hypothesis that autophagic
vacuoles form normally and even with more velocity in cells
from both HD patients and mouse models of HD. These vacuoles
cannot trap aggregatedmutant Htt (Martinez-Vicente et al., 2010).
The authors provided evidence that failure of autophagy in HD
is a complex process. They have demonstrated that, althoughautophagosome formation and degradation are normal in both
murine models and HD patients, cargo recognition is severely
affected. This leads to the accumulation of undegraded cyto-
plasmic cargo (including huntingtin-containting aggregates) that
constitutes a possible damage source in neuronal cells. On the
other hand, results of another study show that elevation in the
lysosomal proteases has helped the mutant Htt clearance from the
HEK cells via macroautophagy (Liang et al., 2011). In line with this
report are data of in vivo and in vitro studies that show the
beneﬁcial effects of different types of autophagy inducers in HD
(Mendelsohn and Larrick, 2011; Wang et al., 2011a). The role of
macroautophagy in HD is brieﬂy summarized in Table 1.
15.4. Convoluted role of autophagy in the etiology and progression of
amyotrophic lateral sclerosis
Degeneration of spinalmotoneurons leads to respiratory failure
and death in ALS. ALS has been considered as a multifactorial
disease with endoplasmic reticulum stress, oxidative damage and
genetic factors being proposed as some of its pathogenic reasons
(Pasinelli and Brown, 2006). It has been established that elevated
levels of aggregated proteins can cause UPS dysfunction (Crippa
et al., 2010a) and subsequently, compensatory activation of
autophagy (Korolchuk et al., 2010). Thus, impairment of UPS
(Cheroni et al., 2005) and induction of autophagy have been shown
in spinal neurons from animal models of ALS (Li et al., 2008) and in
post mortem samples from ALS cases (Sasaki, 2011). Furthermore,
an association between the mutant forms of valosin-containing
protein (VCP) with an autosomal dominant ALS has been observed
(Johnson et al., 2010). VCP, an ATP-driven chaperon is essential for
the maturation of autophagosomes that contain ubiquitin and is
suggested to have a role in the mitochondrial quality control and
autophagy (Yamanaka et al., 2012).
Mitochondrial dysfunction has been offered as a converging
point for the multiple pathways that cause apoptosis activation
and neuronal loss in ALS (Reyes et al., 2010; Shi et al., 2010). The
role of disturbance in the mitochondrial function and transport in
the pathogenesis of ALS has been revealed using transgenic SOD1
mice as a familial model of ALS (Magrane et al., 2009). The cause of
mitochondrial malfunction may be linked to the accumulation of
aggregated misfolded proteins, frequently SOD1 and TAR DNA-
binding protein 43 kDa (TDP-43) (Neumann et al., 2006; Shi et al.,
2010). These aggregates form in the ubiquitin-containing inclu-
sions in cell bodies and axons of motoneurons (Neumann et al.,
2006). Notably, SOD1 is basically a cytosolic protein but it partly
deposits in the intermembrane spaces of mitochondria in mutant
SOD1 transgenic mice, a fact that can explain its deleterious effect
on the mitochondrial function (Magrane et al., 2009).
Induction of autophagy, elimination of damaged mitochondria
and aggregated proteins has beneﬁcial effects in slowing the ALS
progression (Crippa et al., 2010b; Fornai et al., 2008; Hetz et al.,
2009). Although autophagy dysregulation has been proposed as a
pathogenic base of ALS (Reviewed in Chen et al., 2012), knocking-
out ofmotor neuron-speciﬁc autophagymachinery failed to induce
ALS in mice. In the same study, ablation of the UPS in motor
neurons reproduced ALS (Tashiro et al., 2012). Additionally, no
systemic macroautophagy dysfunction has been detected in
lymphomononuclear cells of ALS patients (Sala et al., 2012).
Another study showed that daily consumption of lithium delayed
ALS progression in affected humans. This neuro-protective effect
was accompanied by the activation of autophagy inmotor neurons
in G93A mouse model of ALS (Fornai et al., 2008). Upregulation of
autophagic genes displays similar outcomes in Caenorhabditis
elegans model of ALS (Li et al., 2013).
Autophagy inducers like trehalose (Gomes et al., 2010) and
resveratrol (Kim et al., 2007) have also shown beneﬁcial effects by
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However, rapamycin which is a mTOR dependent inducer of
autophagy, has had detrimental effects on motor neurons in the
SOD1 mouse model of ALS (Zhang et al., 2011). Results of a recent
study show that this controversy may be related to the stage of the
disease. Accordingly, food restriction, another established autop-
hagy inducer, show potential protective effects on the spinal cord
of SOD1-G93Amice, only at onset stage but not at pre-end stage of
ALS (Zhang et al., 2013). Table 1 brieﬂy summarizes the role of
macroautophagy in ALS.
15.5. Autophagy and neuroinﬂammation
As we have described before, neuroinﬂammation is implicated
in the progressive nature of several neurodegenerative disorders
and is described in almost all lysosomal storage diseases (LSDs)
with neurological involvement (Farfel-Becker et al., 2011; Jeya-
kumar et al., 2003; Ohmi et al., 2003). Autophagy may play an
essential function in the control of inﬂammation and immunity.
Gutierrez and colleagues demonstrated that autophagy was
involved in the removing microbes such as mycobacterium
tuberculosis (Gutierrez et al., 2004a). Yu et al. (2006) showed
that autophagy selectively degraded catalase leading to the
accumulation of ROS and non-apoptotic death of macrophages.
Therefore, therapeutic strategies to inhibit neuroinﬂammation by
the regulation of autophagy might be helpful in seeking effective
new target treatments for neurodegenerative diseases.
Both, oxidative stress and neuroinﬂammation have been
involved to advance cognitive destruction in AD as they can
facilitate Ab generation and NFTs formation (Agostinho et al.,
2010; Cai et al., 2013) and ﬁnally throw in to the progressive
cognitive deﬁcits of AD (Majumder et al., 2011; Rasool et al., 2012).
Previous reports have revealed that autophagy inducer rapamycin
recovers learning process and memory in the course of the
inhibition of Ab and tau accumulation by interfering with several
signaling cascades (Liu et al., 2013b) that include interactions
between oxidative stress and neuroinﬂammation (Galasko and
Montine, 2010; Galimberti and Scarpini, 2011). Therefore,
rapamycin is thought to exert its neuroprotective actions via its
antioxidant, anti-inﬂammatory, and autophagy inducing capabili-
ties (Chen et al., 2013; Marobbio et al., 2012).
16. Apoptosis and neurodegenerative disease
16.1. Apoptosis in Alzheimer’s diseases
The exact mechanisms of neuronal degeneration in AD are still
unknown. Available data presents some abnormalities in the
metabolism of amyloid precursor protein (APP) as a causative
factor, which can results in mitochondrial dysfunction and
eventually cell death. Whenever there is an overexpression of
APP, its metabolite, Ab peptide, will overload. Toxic effect of Ab is
manifested by ROS generation, apoptosis induction and impaired
memory (Lustbader et al., 2004). Althoughmost deleterious effects
of Ab is attributed to Ab deposits (Abramov et al., 2004; Picone
et al., 2009), extracellular Ab (i.e. released from dying cells) can
enter other cells and cause mitochondrial dysfunction (Ana-
ndatheerthavarada et al., 2003; Picone et al., 2009; Resende et al.,
2008b). Therefore, APP has been the subject of intense research as
one possible cause for mitochondrial dysfunction in AD (Fuchs and
Steller, 2011; Hirai et al., 2001).
With this regard, in vivo and in vitro experiments have shown
that soluble Ab impairs mitochondria metabolism by decreasing
cytochrome oxidase activity and increasing hydrogen peroxide
generation (Manczak et al., 2006). Moreover, Ab can interact with
Cyclophilin-D, the mitochondrial modulatory component ofmitochondrial mPTP, and increase synaptic stress with disturbing
effects on learning and memory of AD patients (Du et al., 2008). In
an animal model, knocking down of Cyclophilin-D encoding gene
ameliorated deleterious effects of Ab (Cecconi et al., 1998). A
recent study conducted on HT22 line of murine hippocampal cells
and the APP/PS mouse model of AD have also shown that
cytochrome c release from the mitochondria was mediated not
only by the exogenous treatment of Ab1–42, but also by the
mitochondria-speciﬁc accumulation of Ab1–42. The same work
also revealed that exogenously treated Ab1–42 enters the
intracellular compartment through clathrin-mediated endocyto-
sis, and that mitochondria-speciﬁc Ab1–42 accumulation was a
sufﬁcient event to induce not only mitochondrial dysfunction, but
also neuronal death (Cha et al., 2012).
Death receptors DR4 and DR5 were shown to mediate cerebral
microvascular endothelial cell apoptosis that was induced by
oligomeric Ab peptide (Fossati et al., 2012). Ab peptide also
induces caspase-3-dependent apoptosis in primary culture of
astrocytes. Overexpression of wild-type APP in CHO cells also
induced caspase-3 activation and nuclear fragmentation. In this
context, caspase-3 activated apoptosis was due to the aggregation
of APP in mitochondria. The ﬁnding that opening of mPTP was
glutathione-sensitive suggests a novel pro-oxidant role for APP
(Bartley et al., 2012). Results of another study on the primary rat
cortical neuron cultures, suggested AIF-induced death as the
mechanism of caspase-independent apoptosis which happens
following Ab treatment (Yu et al., 2011).
RanBP9 is a scaffold protein that is increased in brains of AD
patients (Lakshmana et al., 2010). Levels of RanBP9 also increase by
four-fold in brains of FAD mutant APP transgenic mice. The same
study also revealed that RanBP9 activates/dephosphorylates
coﬁlin, which is a crucial tuner of mitochondrial induced apoptotic
cell death (Klamt et al., 2009) and actin dynamics (Kim et al., 2010).
Endoplasmic reticulum (ER) stress has been presented as another
causative factor in AD by affecting tau phosphorylation and Ca2+
regulation (Resende et al., 2008a,b). The E693dmutation in APP in
transfected HEK293 and COS-7 cells caused accumulation of Ab in
ER, subsequent increased ER stress markers, such as Grp78 and
phosphorylated eIF2a, and ﬁnally stress-induced apoptosis in the
ER (Nishitsuji et al., 2009).
16.2. The role of apoptosis in the etiology and progression of
Parkinson’s disease
Although a spectrum of cell death have been detected in PD
(Reviewed in Perier et al., 2012) apoptosis rather than necrosis is
considered as the dominant mechanism for neurodegeneration in
PD (Reviewed in Kountouras et al., 2012). Furthermore, in a cellular
model of PD, caspase-independent apoptosis has been shown even
in the presence of cytochrome c release following complex I
inhibition. However, the mechanism underling pathogenesis of PD
is still unknown. In addition to aging, epidemiological studies have
introduced several factors that increase susceptibility to PD
including pesticides, herbicides and industrial chemicals (Ascherio
et al., 2006; Schapira, 2006).
Various genetic mutations have been found in familial forms of
PD. The most common mutation occurs in dardarin/LRRK2
encoding gene (PARK8) that appears to be a member of
multifunctional Ras/GTPase family (Zimprich et al., 2004). This
research area is now a matter of strong scientiﬁc interest, as
genetic factors have been found to play the key role in other
diseases (Wiechec, 2011; Wiechec and Hansen, 2009). In situ
hybridization-based studies displayed high expression of LRRK2 in
dopamine-innervated areas in brains of both patients with PD and
controls (Galter et al., 2006). The most convincing evidence for the
role of LRRK2 in PD obtained from a cellular study that showed the
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with death domain (FADD) resulted in the switching-on of the
extrinsic apoptotic pathway via caspase-8 activation (Ho et al.,
2009). Another recent study on the human neural stem cells
pointed to the damaging effect of mutant LRRK2 on nuclear
envelope that may be a causative factor in pathogenesis of PD, but
they reported no evidence of apoptosis (Liu et al., 2012).
Aggregation of wild-type and mutant forms of a-syn in Lewy
bodies is a hallmark of a-synucleinopathies like PD. These
aggregates have been detected throughout the nervous system
(Galvin et al., 1999). Alpha-syn seems to act as a molecular
chaperone for SNARE synaptic proteins (Burre et al., 2010; Chandra
et al., 2005). Increased level and accumulation of mutateda-syn in
transgenic mice caused paralyzes and death (Giasson et al., 2002).
A dopaminergic neuronal cell study revealed that a-syn can
downregulate expression of PRC-d, a proapoptotic oxidative
stress-sensitive kinase, which suppress apoptosis in these cells
(Jin et al., 2011). This ﬁnding seems to be in contrastwith outcomes
of the other cellular studies performed on SH-SY5Y neuroblastoma
cells that showed overexpression of a-syn aggravated manganese
induced apoptosis (Li et al., 2010).
Mutations in PARK2 gene that encodes parkin protein are a
potent risk factor for PD. (Kitada et al., 1998). Parkin works as an
ubiquitin E3 ligase with a-syn being one of its substrates.
Therefore, mutation in this protein can result in accumulation of
its substrates including a-syn (Yamamoto et al., 2005). Suppres-
sion of parkin in a cellular model of PD was accompanied by
accumulation of Peal-R, another substrate of parkin. This causes
accumulation of unfolded proteins in the ER and consequently
increased rate of apoptosis (Zou et al., 2012). Parkin and its partner
PIKN1, a mitochondrial kinase, co-work in a pathway to control
mitochondria morphology and functionality (Geisler et al., 2010;
Lazarou et al., 2012). Mounting evidences imply that PINK1 has a
role in Ca2+ efﬂux in mitochondria. Deﬁciencies in PINK1 result in
accumulation of Ca2+ in mitochondria and increased generation of
ROS followed by opening mPTP and elevation in the rate of cell
death (Akundi et al., 2011; Gandhi et al., 2009; Heeman et al., 2011;
Marongiu et al., 2009).
DJ-1 is another mitochondrial protein with protective effects,
partly ascribed to its function as an oxidative stress-induced
chaperon (Zhou et al., 2006). DJ-1 mutations are associated with
familial PD (Bonifati et al., 2003). A dopaminergic cell study
attributed this neuroprotective effect of DJ-1 to its activating effect
of the ERK pathway that results in mitophagy induction (Gao et al.,
2012). DJ-1, PINK1 and parkin all are localized inmitochondria that
suggest strong linkage of PD with mitochondrial dysfunction.
Indeed, when mitochondria encounter an insult that makes it
defective, reduction in membrane potential makes it targeted by
PINK1 and parkin for mitophagy, a phenomenon that prevent
apoptosis when insult is not so deleterious (Schapira, 2012; Youle
and van der Bliek, 2012).
Existence of a strong link between ER stress and induction of
apoptosis has been previously demonstrated (Nakagawa et al.,
2000; Puthalakath et al., 2007). Recent evidences however, point to
beneﬁcial effects of mild ER stress on cell survival. Protective
effects of ER stress induced by H2O2 have been shown in an in vitro
study (Pallepati and Averill-Bates, 2011). Consistently, in animal
and cellular model studies of PD ER stress has had neuroprotective
effects by induction of autophagy (Fouillet et al., 2012;Matus et al.,
2012).
16.3. Excitotoxicity-triggered apoptosis and other effects of mutated
huntingtin protein in Huntington’s disease
Much evidence supports the role of apoptosis in neurodegen-
eration observed in HD (Sawa et al., 1999; Vis et al., 2005;Wellington et al., 2000a). However, in comparison to other
neurodegenerative disease, few direct studies have been done in
this area. Caspases (i.e. caspase-6) proteolytically cleave Htt (Kim
et al., 2001; Wellington et al., 2000b) and release an N-terminal
fragment containing the pQ motif, thus generating toxic mHtt
fragments (Ratovitski et al., 2007). Overexpression ofwild-type Htt
had a protective effect in transgenic mice model of HD, by
preventing NMADRs excitotoxicity (Leavitt et al., 2006).
Several mechanisms have been suggested to explain induction
of apoptosis in HD. In a YAC transgenic HD mouse model,
excitotoxicity mediated by glutamate NMDA receptors lead to
intracellular calcium elevation, mitochondrial dysfunction and
ﬁnally apoptosis in a pQ length-dependent manner (Shehadeh
et al., 2006). Along these lines, another in vivo study reported
increased extrasynaptic NMDA receptor expression as well as
associated reductions in nuclear CREB activation in striatum of HD
mouse. These changes correlated with mutation severity, were
dependent on the cleavage of mHtt by caspase-6, and resulted in
manifestation of the disease (Milnerwood et al., 2010). The exact
link betweenHtt, caspase cleavage, and caspase activation patterns
in the pathogenesis of HD is poorly understood, however, the
activation of caspase-6, but not caspase-3, occurs before onset of
mobility abnormalities in human and murine HD brain.
Inositol hexakisphosphate kinases (InsP(6)Ks) has been pro-
posed as another apoptosis triggering factor, at least in a cellular
models of AD. InsP(6)Ks promote apoptosis in a caspase-
independent manner. Under stress conditions, an isoform of
InsP6Ks, Inositol hexakisphosphate kinase type 2 (InsP(6)K2),
mediates apoptotic cell death via its translocation from the nucleus
to the cytoplasm. While InsP(6)K2 is localized in the nucleus of
normal lymphoblasts, this enzyme is observed mainly in the
cytoplasm of HD lymphoblast cells. This ﬁnding may suggests a
role for InsP6K2 activation in the pathogenesis of HD (Nagata et al.,
2010).
Huntingtin interacting protein (HIP-1) also contributes to
induction of caspase-dependent apoptosis when its death-effector
domain interacts with mHtt. Subsequent interaction of HIP-1 with
its molecular partner HIPPI launches apoptosis (Gervais et al.,
2002; Hackam et al., 2000). Whereas coexpression of HIP-1 and
wild-type Htt reduces proapoprotic effect of HIP-1 (Choi et al.,
2006). Findings of other studies however, imply that HIP-1may act
as an antiapoptotic factor in some experimental models (Bradley
et al., 2007a, 2007b).
16.4. Amyotrophic lateral sclerosis and the role of apoptosis in the
onset and progression of the disease
A spectrum of PCD have been shown in ALS using animal- and
cellular models as well as postmortem tissues (Reviewed inMartin
and Liu, 2004). Studies on spinal cord of SOD1 G93A transgenic
mice and the most common mutations found in familial forms of
ALS, revealed activation and translocation of AIF from mitochon-
dria to the nucleus of motor neurons (Oh et al., 2006). Nuclear
localization of AIF leads to induction of chromatin condensation,
DNA fragmentation and ﬁnally caspase-independent apoptosis
(Daugas et al., 2000). Tanaka and colleagues used a mice model of
ALS to show that AIF and cyclophilin A co-translocate to the
nucleus and cause motor neuron death (Tanaka et al., 2011).
In ALS, speciﬁc degeneration of motor neurons is associated
with dysregulation of intracellular Ca2+ and excitotoxicity. These
events point to the role of mitochondrial dysfunction and
apoptosis. However, no strong and direct evidence has been found
yet in human ALS pathophysiology that such events are important
for the onset and/or progression of the disease. Muscle biopsy
analysis revealed an increase in the intracellular level of Ca2+ and
mitochondrial volume in motor nerve terminals of ALS patients as
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study, measurement of mitochondrial membrane potential of
platelets, revealed severe depolarization of mitochondrial mem-
brane and apoptosis in platelets of ALS patients as compared to
controls (Shrivastava et al., 2011).
Glutamate-mediated excitotoxicity is another possible mecha-
nism that is proposed in the pathogenesis of ALS (Reviewed in
Rowland and Shneider, 2001). Motor neurons are more susceptible
to glutamate excitotoxicity because of low GluR2 number or
decrease in RNA editing of AMPA receptors on their surface, that
make them vulnerable to elevated Ca2+ entry and mitochondrial
impairment (Kwak and Kawahara, 2005). Pathological studies
showed that increase in intracellular Ca2+ level leads to elevation of
ROS production in mitochondria by activating mitochondrial
permeability transition (Hansson et al., 2008). Low expression of
calcium binding proteins in some subpopulations of motor
neurons decreases their Ca2+ buffering capacity and makes them
more susceptible to excitotoxicity (Reviewed in Bogaert et al.,
2010). With this regard, ‘‘toxic shift of calcium’’ has been proposed
as a new hypothesis inﬂuencing motor neuron death in ALS. This
hypothesis offers a Ca2+ cycle between ER and mitochondria that
maintains Ca2+ homeostasis in motor neurons (Reviewed in
Grosskreutz et al., 2010).
The role of X-Box binding protein-1 (XBP-1) in ALS pathophysi-
ology has recently been proposed. XBP-1 works in UPR pathway as
a transcription factor. Results of a study on a mice model of ALS
that is deﬁcient in XBP-1, showed that the observed increase in
mitophagy was associated with a decline in protein aggregation
and disease progression (Matus et al., 2009). This ﬁnding implies
that cross-talk may exist between UPR-autophagy pathways. On
the other hand, treatment of SOD1 G93A mice with rapamycin
made mitochondrial abnormalities worse. Bax level elevation and
caspase-3 activation culminated in more motor neuron degenera-
tion via apoptosis, a ﬁnding that suggests an impairment of
autophagy pathway in this model of ALS (Zhang et al., 2011).
Strong evidence obtained from a longitudinal analysis proposed
that different responses to ER stress in subpopulations of motor
neurons affect the manifestation and progression of ALS (Saxena
et al., 2009). In mutated superoxide dismutase (mSOD1) mice,
accumulation of mSOD1 resulted in ER stress. Accumulating data
suggest that ER stress may activate the mitochondrial apoptotic
pathway resulting in the release of cytochrome c from the
mitochondria (Heath-Engel et al., 2008; Hetz, 2007). ER stress
occurs early in pathogenesis of ALS in SOD1 G93A transgenic mice
(Atkin et al., 2006). Further studies have demonstrated that
proapoptotic BH3-only proteins, Bim or Puma, are required for ER
stress-induced apoptosis (Reimertz et al., 2003; Schapira, 2012).
Bim is implicated in the molecular processes associated with
pathology and cell death in transgenicmice expressing SOD1 G93A
(Hetz et al., 2007). Bim appears to be the intermediary between ER
stress and mitochondrial apoptosis in cells containing potentially
toxic mSOD1 proteins (Soo et al., 2012). This ﬁnding validates the
data regarding the ER stress-induced apoptosis action of CHOP on
the expression of multiple pro-apoptotic BH3-only proteins in
neuronal cells (Ghosh et al., 2012) (Table 2).
17. Connection between age-related neurodegenerative
disorders and cell aging/cell senescence
Numerous studies suggest that age related neurodegenerative
disorders cause cell aging and cell senescence and the latter might
eventually lead to apoptosis or other forms of cell death. For
instance, as the age of the human beings progress there is an
increase in the production of reactive oxygen species and hence
causing oxidative damage to nucleic acids especially RNA
(Nunomura et al., 2012). This has been demonstrated in neuronsof human and rodent brains. In patients suffering from neurode-
generative disorders such as AD, PD, and ALS, there is a prominent
increase in the neuronal RNA damage when compared to normal
aging people (Nunomura et al., 2012). Oxidative RNA modiﬁcation
occurs not only in RNA that makes proteins but also in non coding
RNA leading to aberrant expression ofmicroRNAs and proteins that
initiate cellular pathways and ultimately leading to cell death
(Nunomura et al., 2012). In another study it has been shown that
telomere, which is a repetitive DNA structure present at the end of
the chromosomes becomes shorter with aging because of the
defect in replication process (Maeda et al., 2012). The telomere
shortening is accelerated in brain-associated illnesses such as in
PD. The peripheral leukocytes of Japanese female patients with PD
have fewer large telomeres and an increase in the hypomethylated
subtelomeres in short telomeres when compared to the healthy
control patients (Maeda et al., 2012). These results indicate that
pathogenesis associated with neurodegenerative disorders could
increase the structural changes in the telomeres thereby causing
cells with smaller telomeres to die quickly (Maeda et al., 2012).
Thus, from these evidences one could argue that drugs that delay
the aging process could also prevent or at least postpone the age
related disease such as neurodegenerative disorders. Numerous
studies have shown that caloric restriction delays aging-induced
phenotypes in a variety of species such as rats, mice, ﬂies and
primates (Blagosklonny, 2012). Furthermore, it has been demon-
strated that inhibition of mTOR pathway extends the life span of
yeast, ﬂies and mice (Blagosklonny, 2012).
18. The potential of autophagy- and apoptosis modulation as a
treatment strategy in neurodegenerative diseases
In previous paragraphs, we have highlighted the effects of
autophagy and apoptosis on the etiology, and/or progression of
neurodegenerative diseases. Below, we discuss how autophagy or
apoptosis modulation may therapeutically affect the progress of
those diseases.
18.1. Autophagy modulation and Huntington’s diseases treatment
strategies
There are no effective treatments that would reverse the
nuerodegeneration caused by HD. pQ expanded Htt aggregates
accumulate in the brain and cause intraneuronal inclusions that
result in neuronal loss and thereby cortical degeneration.
Reduction of the content of mutant Htt aggregates can decrease
the harmful effects caused by this disease. The Htt aggregates are
degradable by autophagy. Although, macroautophagy cannot
degrade nuclear inclusions (Iwata et al., 2009), some studies have
found that autophagy is activated by Htt accumulation in the
cytoplasm of striatal cells and participate in the degradation of Htt
(Qin et al., 2003). Further studies conﬁrmed the role of autophagy
in the elimination of pQ repeats-carrying fragments (Ravikumar
et al., 2002) and reduction of its toxicity (Liang et al., 2011). Hence,
it has been demonstrated in cell models, transgenic mouse and
human brain that the aggregated pQ proteins in the inclusions
sequester mTOR. Sequestration of mTOR impairs its kinase activity
and induces autophagy (Ravikumar et al., 2004). A recent study
showed that rilmenidine, an anti-hypertensive drug induced
autophagy in HD model mice and also in primary neuronal cell
cultures (Rose et al., 2010). Administration of this drug attenuated
signs of HD in mice models and also reduced aggregates of mutant
Htt (Rose et al., 2010). Thus, rilmenidine can be considered as a
drug for the treatment of HD and related conditions. Another
recent study provided evidence that overexpression of full-length
Huntington protein lacking pQ stretch in HD mice model
signiﬁcantly reduced the mutant Htt aggregates and also extended
Table 2
List of some of the potential apoptotic drugs used for treatment of neurodegenerative diseases.
Drug Mechanism of action References
Minocycline It prevents release of cytochrome c from mitochondria
Increases the expression anti-apoptotic protein Bcl-2 and inhibits the activity of
caspases-1 and -2
Kim and Suh (2009) and
Seidl and Potashkin (2011)
CEP-1347 Inhibits the mixed lineage kinase (MLK) family, thereby preventing apoptosis Wang et al. (2004)
Rasagiline Selective and irreversible inhibitor of MAO-B
Inhibits apoptosis by activating protein kinase C and by down regulating FAS and
Bax family of proteins
Youdim et al. (2005)
Selegiline Selective inhibitor of MAO-B
Inhibits apoptosis by up-regulating regulating Bcl-2 protein
Minimize loss of mitochondrial potential
Inhibit the activity of caspases
Tatton and Chalmers-Redman (1996)
Coenzyme Q 10 Protect neurons from oxidative stress by scavenging reactive oxygen species Choi et al. (2012)
Melatonin It is a chemical compound secreted by pineal gland
Prevents the oxidative stress by stimulating the synthesis of antioxidant enzymes
such as super oxide dismutase and glutathione peroxidase
Pandi-Perumal et al. (2012)
Resveratrol A chemical compound present in grapes, red wine and other fruits.
Inhibits the oxidative stress by up regulating the anti-oxidant system
Khan et al. (2010)
Lithium It rescues spinal cord mitochondria in ALS
Facilitates the clearance of SOD1 and ubiquitin in ALS motor neurons
Pandi-Perumal et al. (2012)
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(Zheng et al., 2010). Mice carrying over-expressed HD also showed
normal lipofuscin levels in the brain and also an increased steady
level of autophagy. Thus, upregulation of autophagy can expand
the life span of HD mice by clearing out aggregates containing
mutated Htt (Zheng et al., 2010).
Small molecule enhancers of rapamycin (SMERs) augment
autophagy and therefore have therapeutic potential in the
treatment of various neurodegenerative disorders such as HD
and PD (Floto et al., 2007). However rapamycin’s side effects such
as immuno-suppression at early stages of treatment prevented its
use in treating neurodegenerative diseases. Three SMERs, which
act independently of mTOR pathway, have been identiﬁed (Floto
et al., 2007). These SMERs clear the mutated Htt in HD cell models
and extended the lifespan of the cells (Floto et al., 2007). So SMERs,
which act independently of the mTOR pathway, could be used as
therapeutic molecules in treatment of degenerative diseases.
18.2. Alzheimer’s diseases – autophagy modulation as therapy
approach
Large accumulation of autophagosomes in dystrophic neuritis
was observed in the animal models of AD and in postmortem
brains of AD patients. Dysfunction in macroautophagy may
enhance g-secretase activity, which in turn increases Ab by
cleaving amyloid-b precursor protein (APP) (Ohta et al., 2010).
Furthermore, the AD drug (galanthamine hydrochloride) shows
inhibitory effects on autophagy (Lipinski et al., 2010), suggesting
that decreased formation of autophagosomesmay decline levels of
Ab (Lipinski et al., 2010). These ﬁndings conﬁrm conclusions from
other studies that autophagosome may be an intracellular Ab
reservoir which form when maturation of autophagosomes to
autolysosomes is impaired (Yu et al., 2005). Moreover, despite
autophagy is downregulated in the normal aging brains (Lipinski
et al., 2010), it is transcriptionally upregulated in the brains of
AD patients (Lipinski et al., 2010). This may be a way to
compensate for the deﬁcit in UPS (Korolchuk et al., 2010). In
contrast, beclin-1 (ATG6) level, a key component for autophago-
some formation in the autophagy canonical pathway, is reduced
in affected brain regions of AD patients (Pickford et al., 2008).
Defects in the autophagy and accumulation of autophagosomes
are attributed to the decreased in expression of beclin-1. Hence,
induction of autophagy using small molecules that can critically
regulate autophagy can be a better therapeutic target for
controlling AD.Resveratrol is a phenolic compound abundant in red wine,
grapes, and numerous fruits. Because of its antioxidative and anti-
inﬂammatory properties it is widely used as an alternative therapy
for various pathologies including cardiovascular diseases and
cancer. As mentioned previously, in the course of various
neurodegenerative disorders, including AD, the excessive produc-
tion of reactive oxygen species in brain could be observed. The
reactive oxygen species-scavenging properties of resveratrol
indicate that it could be used as a therapeutic agent in afore
mentioned pathologies. Neuritic plaques composed mainly of Ab
in the brain are an early and invariant neuropathological feature of
AD (Ono et al., 2006). Resveratrol lowers the levels of secreted and
intracellular Ab peptides produced by various cell lines (Mar-
ambaud et al., 2005). The Ab-lowering effect of resveratrol relies
not on the inhibition of Ab production, but on the promotion of its
intracellular degradation via proteasome-based mechanism. This
was shown in experiments where resveratrol-induced decrease of
Ab, could be prevented by proteasome-selective inhibitors. These
ﬁndings demonstrate a proteasome-dependent anti-amyloido-
genic activity of resveratrol, and suggest that this natural
compound has a therapeutic potential in AD (Marambaud et al.,
2005). In other studies, the phytochemical resveratrol and its
analogous (RSVA314 and RSVA405) have shown potent stimula-
tory effects on autophagy and Ab clearance (Vingtdeux et al.,
2011). It seems that resveratrol effects are mediated by its impact
on the AMPK signaling pathway that controls Ab metabolism
(Vingtdeux et al., 2010). However, these effects of the resveratrol
may also be partly attributed to the increased levels of
neurotrophic factors (Rahvar et al., 2011). This phytochemical
may induce BDNF expression, and ameliorate synaptic degenera-
tion and memory deﬁcits in an transgenic (Tg2576) mouse model
of AD (Iwasaki et al., 2012). In animal model of AD and tau
pathology, resveratrol reduced neurodegeneration in hippocam-
pus, abrogated the learning deﬁcit, and decreased the acetylation
of SIRT1 substrates PGC-1a and p53 (Kim et al., 2007). Resveratrol
is presently in phase II clinical trials for treating patients with mild
to moderate AD.
Lithium, a compound used as a mood stabilizer, is neuropro-
tective in many of the disease models (Fornai et al., 2008). Thus,
daily administration of lithium in human Alzheimer patients
delayed disease progression. Apart from that, in a genetic mouse
model of Alzheimer disease, lithium treatment induced a marked
neuroprotection, as well as a delayed progress of the disease along
with an increase in the lifespan of the animals (Fornai et al., 2008).
Such effectswere concomitantwith activation of autophagy and an
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suppressed reactive astrogliosis (Fornai et al., 2008). These results
showed promising evidence for lithium as a drug for the treatment
of AD.
18.3. Parkinson’s disease – therapeutic effect of autophagy
As mentioned earlier, PD is a neurodegenerative disorder
marked by loss of dopaminergic neurons in the brain-stem and the
presence of intraneuronal inclusions designated as Lewy bodies
(Lee et al., 2009). Overexpression ofa-syn in the neuronal cells can
lead to lysosomal accumulation and alterations in autophagy
(Spencer et al., 2009). Expression of beclin-1 in cells that
overexpress a-syn reduced accumulation of a-syn in these cells
and rescued them from lysosomal accumulation and alterations in
autophagy (Spencer et al., 2009). Introduction of belcin-1 gene into
the brain of a-syn transgenic mice ameliorated the synaptic and
dendritic pathology and enhanced lysosomal activation and
reduced alterations in the autophagy pathway. These results
provide evidence that beclin-1 can be a novel therapeutic target for
the treatment of PD (Spencer et al., 2009).
Trehalose is a non-reducing disaccharide present in many
organisms and it induces autophagy (Sarkar et al., 2007). Trehalose
induced autophagy enhanced the clearance of mutant forms of
botha-syn and huntingtin. These results provide the evidence that
trehalose can be used as a small molecule in the treatment of
neurodisorders like PD (Sarkar et al., 2007).
18.4. Apoptosis modulation and neurodegenerative diseases
treatment strategy
Minocycline, a member of tetracycline-family of antibiotics,
inhibits apoptosis by preventing oxidative stress, blocks the
release of cytochrome c from mitochondria and disrupts the
activation of caspase-3 (Kim and Suh, 2009). It also increases the
expression of anti-apoptotic protein Bcl-2 and inhibits the
expression of caspases-1 and -2 (Kim and Suh, 2009). Because of
its role as an anti-apoptotic molecule it is tested in several models
of neurodegenerative disorders such as HD, AD and PD. In all these
animal models it prevented the aggravation of disease by reducing
apoptosis. In small clinical trials minocycline was proven effective
in treatment of PD and AD (Ono et al., 2006). Hence, minocycline is
now in phase II and phases III clinical trials for several other
diseases such as spinal cord injury and stroke.
CEP-1347 is an inhibitor of Mixed Lineage Kinase (MLK) family
of kinases. These kinases potentiate neuronal cell death signal
transduction pathway. So inhibiting this pathway can be a good
therapeutic target in prevention of various neurodegenerative
diseases. Experimental evidence shows that CEP-1347 prevents
apoptosis in neurons by inhibiting MLK family of kinases (Wang
et al., 2004). In one clinical study, the researchers performed a
randomized, blind, placebo-controlled study assessing the safety,
tolerability, pharmacokinetics, and acute symptomatic effects of
CEP-1347 in 30 patients with PD (Wang et al., 2004). In this short-
term study, CEP-1347 was proven to be safe and well tolerated in
the patients with PD (Wang et al., 2004). However, a larger clinical
study proved that CEP-1347 is not effective for treating the
patients who suffer from PD (2007).
Rasagiline (N-propargyl-1R-aminoindan) is a selective and
irreversible inhibitor of monoamine oxidase B (MAO-B). MAO-B
catalyzes breakdown of dopamine in brain by releasing hydrogen
peroxide, which is in part responsible for the oxidative damage
in PD. In neuronal cells, rasagiline inhibited apoptosis induced
by neurotoxins by preventing the mitochondrial permeability
transition and by up-regulating anti-apoptotic Bcl-2 proteins
(Maruyama et al., 2002). Their neuroprotective effects are also dueto activation of protein kinase C and by downregulating apoptosis
inducer molecules such as Fas and Bax (Youdim et al., 2005). In the
ﬁrst clinical study in 2002, rasagiline was used as treatment option
for PD and was more effective in the patients with early PD (2002).
In one of the recent clinical studies involving rasagiline (ADAGIO
study), the early treatment with 1 mg per day dosage showed
beneﬁts, however 2 mg per day dosage did not have the same effect
(Olanow et al., 2009). Because the two doses were associated with
different outcomes, the study results must be interpreted with
caution (Olanow et al., 2009). In an extension of ADAGIO, study
authors randomly selected 1176 patients with untreated early PD
and investigated effect of rasagiline 1 mg or 2 mg per day for 72
weeks (early-start group) (Rascol et al., 2011). Another group was
treated with placebo for 36 weeks followed by 1 mg or 2 mg per
day for next 36 weeks (delayed-start group). From these studies,
authors concluded that rasagiline delayed the need for symptom-
atic antiparkinsonian drugs and improved (uniﬁed PD rating scale)
UPDRS ADL (daily living activities) scores, an effect clearly visible
during the placebo-controlled phase of the studies (Rascol et al.,
2011).
Selegiline is another selective inhibitor for MAO-B, which is
similar to rasagiline that also exhibits anti-apoptotic activity.
Selegiline treatment decreases both the oxidative and nutritive
stress by lowering the H2O2 overproduction as well as diminishes
the amount of reactive oxygen- and nitrogen species (Tipton et al.,
2004). Superoxide anion radicals can react with nitric oxide (NO)
and form peroxynitrate, which spontaneously decomposes to OH
and NO2 (Tipton et al., 2004). Pretreatment with selegiline can
protect neurons against a variety of neurotoxins, such as 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopa-
mine, N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4),
methyl-beta-acetoxyethyl-2-chloroethylamine (AF64A), and 5,6-
dihydroxyserotonin, which damage dopaminergic, adrenergic,
cholinergic, and sertoninergic neurons, respectively (Ebadi et al.,
2002). Selegiline reduces the production of reactive oxygen
species, upregulates superoxide dismutase and catalase, and
suppresses nonenzymatic, iron-catalyzed auto-oxidation of dopa-
mine. It delays apoptosis in serum-deprived cells, and blocks
apoptosis-related fall in the mitochondrial membrane potential
(Ebadi et al., 2002). The protective action of selegiline against
apoptosis can be attributed to the upregulation of Bcl-2 proteins
(Tatton and Chalmers-Redman, 1996). Selegiline is currently in
clinical trials for the treatment of PD (Ondo et al., 2011).
Coenzyme Q10 is another compound currently considered as a
potential experimental drug for the treatment of neurodegenera-
tive diseases. Coenzyme Q10 resides in the inner mitochondrial
membrane as a part of electron transport chain and participates in
aerobic respiration. Many of the neurodegenerative disorders are
characterized by defects in the innermitochondrialmembrane and
in oxidative phosphorylation (Camins et al., 2010). Coenzyme Q10
is shown to protect neurons from oxidative stress. Recently, a
multicenter, clinical study tested nanoparticular coenzymeQ10 for
the treatment of PD-patients (Storch et al., 2007). The study
concluded that nanoparticular coenzyme Q10 at a dosage of
300 mg/day is safe and well tolerated and leads to plasma levels
similar to 1200 mg/day dosage of a standard formulation.
Coenzyme Q10 applied in such doses and the nanoparticular
formulation does not cause side effects in mid-stage PD (Storch
et al., 2007). Coenzyme Q10 was also clinically tested on patients
with HD (Shults, 2003).
Melatonin, which is secreted in a circadian rhythm-regulated
manner by pineal gland in mammalian brain, has ROS scavenging
activity. Because of its anti-oxidative function it can be tested as an
experimental drug in neurodegenerative diseases with ROS
involvement. Its mechanism of action could be attributed to
stimulating the synthesis of antioxidant enzymes including
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tase, and augmenting glutathione level (Pandi-Perumal et al.,
2012). Melatonin preserves mitochondrial homeostasis, reduces
free radical generation and protects mitochondrial ATP synthesis
by stimulating Complexes I and IV activities (Pandi-Perumal et al.,
2012). In one of the animal trials conducted on melatonin in
murine ALS model (SOD1(G93A)-transgenic mice), it delayed
disease progression and extended survival (Weishaupt et al.,
2006). Furthermore the authors showed that in a clinical safety
study long-term high-dose of 300 mg/day melatonin applied per-
rectum was well tolerated during an observation period of up to 2
years. Importantly, circulating serum protein carbonyls, which
provide a surrogate marker for oxidative stress, were elevated in
ALS patients, but were normalized to control values by melatonin
treatment (Weishaupt et al., 2006). This combination of preclinical
effectiveness and proven safety in humans suggests that high-dose
melatonin treatment should be tested in clinical trials aimed at
neuroprotection in ALS. Melatonin also has protective effects in
HD. In a recent study, using R6/2 transgenic-mouse HD model, the
authors demonstrated that melatonin delayed disease onset and
prolonged life span of mice (Wang et al., 2011b). Hence, melatonin
receptor MT1 levels decrease in cultured striate cells, mouse brain,
and human striatum associated with mutant Http-mediated
toxicity, and receptor depletion becomes greater as the disease
progresses. Melatonin administration counteracted MT1 receptor
depletion in experimental models utilizing mutant-Http, both in
vitro and in vivo (Wang et al., 2011b). These results indicate that
melatonin should be clinically tested for the HD therapy.
Melatonin is also effective in protecting the transgenic mice
with AD. Long-term administration of melatonin orally protected
the mice from cognitive deﬁcits and abrogated the rise of markers
of neurodegeneration (Olcese et al., 2009). Furthermore, melato-
nin’s cognitive protection likely involved three complementary
mechanisms: (i) counteracting Ab aggregation, (ii) anti-inﬂam-
matory actions/immunomodulation, and (iii) normalization of
antioxidant defenses (Olcese et al., 2009). Protective effect of
melatonin in PD models as also been recently reported (Wang,
2009).
Besides melatonin, in one recent study, using the 6-hydox-
ydopamine induced PD rat model, authors demonstrated that
resveratrol upregulated the antioxidant defenses and lowered the
dopamine loss (Khan et al., 2010). Elevated level of thiobarbituric
acid reactive substances (TBARS), protein carbonyl (PC), and
activity of phospholipase A2 was attenuated signiﬁcantly in
resveratrol pretreated animals (Khan et al., 2010). Hence,
resveratrol may be used to reduce the deterioration caused by
free radicals thereby preventing subsequent behavioral, biochem-
ical, and histopathological changes that occur during PD (Khan
et al., 2010).
Other potential drugs such as valproic acid, isradipine and
lithium might be used to treat various neurodegenerative
disorders (Khan et al., 2010). Additionally, Hurperzine A, an
alkaloid from Chinese herb and a compound found in Ginko biloba
called EGb, both have anti-apoptotic properties and are tested in
treating various neurodegenerative disorders (Khan et al., 2010).
19. Closing remarks
Neurodegenerative disorders are common, prevalent ailments
of senior years, and they become increasingly widespread as
society’s members’ age advances. These diseases are devastating
not only due to their economic impact on the society (costs of
healthcare, loss of productivity, etc.), but also because they
literarily rob individuals from their identity. Thus, despite societies
around theworld invest billions of dollars in the search for drugs that
would stop, or at least signiﬁcantly slow-down neurodegeneration,the results are unsatisfactory at best. Therefore, it is important to
search for new targets that may be pharmacologically engaged, to
curb the progress of neurodegenerative diseases. As outlined above,
much attention in recent years attracted experimental drugs that
modulate autophagy and/or apoptosis.While the several promising
experimental anti-neurodegenerative drugs have been developed,
one has to exercises some caution with respect to autophagy
modulating drugs. Modulation of autophagy alone will likely not
result in satisfactory clinical effects. This is because of the very
interconnected nature of autophagy, as well as due to the fact that
while a low level of autophagy would generally promote cell
survival; extensive autophagy may actually kill the targeted cell
(Chaabane et al., 2013). Therefore, as shown on some examples in
previous paragraphs, autophagy-modulating anti-degenerative
drugs, when clinically implemented, would most likely show
desired results when their pro-survival effects are strengthened
by conjoined therapies.
Modulation of some autophagy- and apoptosis regulators has to
be done with caution, particularly due to the interconnected
nature of both processes. Some targets like, i.e. the prosurvival
kinase Akt, affect both autophagy and apoptosis. It blocks
autophagy both via Foxo3 inhibition and mTOR activation (Jain
et al., 2013). Cytoplasmic Akt acts as a prosurvival kinase, whereas
when in the nucleus it may contribute to cell death induction
(Maddika et al., 2008). The effects of nuclear Akt on autophagy are
so far largely unknown. While modulators of autophagy and
apoptosis may offer some ‘‘quick ﬁxes’’ for diseases with
neurodegenerative background, the long term solutions in this
area will likely be worked out based on regenerative medicine
(Hombach-Klonisch et al., 2008) and tissue-engineering
approaches.
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